caffeine and Apnea
caffeine has been researched along with Apnea in 302 studies
Apnea: A transient absence of spontaneous respiration.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a randomized controlled trial including preterm infants < 32 weeks' gestation, prophylactic (in the first 72 h of life) versus therapeutic (only if apnea exists or infant requires mechanical ventilation) decision of caffeine was compared." | 9.51 | Prophylactic versus therapeutic caffeine for apnea of prematurity: a randomized controlled trial. ( Elmowafi, M; Mohsen, N; Nasef, N; Nour, I, 2022) |
| " Caffeine is widely used to prevent and treat apnea (temporal cessation of breathing) associated with prematurity and facilitate extubation." | 9.41 | Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity. ( Brattström, P; Bruschettini, M; Davis, PG; Onland, W; Russo, C; Soll, R, 2023) |
| "The purpose of this meta-analysis is to investigate the effect of prophylactic caffeine use in the treatment of apnea and other clinical outcomes in very low birth weight infants." | 9.41 | Effect of prophylactic caffeine in the treatment of apnea in very low birth weight infants: a meta-analysis. ( Jiang, H; Li, Y; Liu, W; Miao, Y; Teng, P; Wang, A; Zhang, Y; Zhao, S, 2023) |
| "Methylxanthines, including caffeine, theophylline, and aminophylline, work as stimulants of the respiratory drive, and decrease apnea of prematurity, a developmental disorder common in preterm infants." | 9.41 | Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants. ( Bruschettini, M; Marques, KA; Moresco, L; Sjögren, A; Soll, R, 2023) |
| "To evaluate the benefits and harms of doxapram administration on the incidence of apnea and other short-term and longer-term clinical outcomes in preterm infants." | 9.41 | Doxapram for the prevention and treatment of apnea in preterm infants. ( Avdic, E; Bruschettini, M; Evans, S; Fiander, M; Pessano, S; Soll, R, 2023) |
| " Although methylxanthines are widely used to prevent and treat apnea associated with prematurity and to facilitate extubation, there is uncertainty about the benefits and harms of different types of methylxanthines." | 9.41 | Methylxanthine for the prevention and treatment of apnea in preterm infants. ( Bruschettini, M; Davis, PG; Fiander, M; Marques, KA; Roehr, CC; Soll, R, 2023) |
| "There is sufficient evidence to support use of caffeine therapy for apnea of prematurity, but practices vary widely when it comes to discontinuing therapy." | 9.41 | Duration of Caffeine for Apnea of Prematurity-A Randomized Controlled Trial. ( Jain, N; Nair, PMC; Nandakumar, A; Pournami, F; Prabhakar, J; Prakash, R, 2021) |
| "Caffeine citrate is used to prevent apnea in premature infants and help in extubation of invasive ventilation, but the optimal dose remains undetermined." | 9.34 | Caffeine citrate maintenance doses effect on extubation and apnea postventilation in preterm infants. ( Chen, P; Huang, L; Wan, L, 2020) |
| "To compare the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants." | 9.34 | [Comparison of the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants: a prospective randomized double-blind controlled trial]. ( Ding, Y; Gan, JM; He, T; Li, W; Liao, ZC; Wang, MJ; Yue, SJ, 2020) |
| "Preterm infants with apnea who were born at less than 32 weeks of gestational age and birth weight ≤1500 g were randomly divided into caffeine citrate prevention group and caffeine citrate treatment group." | 9.34 | Influence of prevention of caffeine citrate on cytokine profile and bronchopulmonary dysplasia in preterm infants with apnea. ( Gao, Z; Han, D; Kou, C; Li, Z; Liu, Z; Wu, W; Zhang, Y, 2020) |
| "To study the clinical effect and safety of different maintenance doses of caffeine citrate in the treatment of apnea in very low birth weight preterm infants." | 9.30 | [Clinical effect and safety of different maintenance doses of caffeine citrate in treatment of apnea in very low birth weight preterm infants: a prospective randomized controlled trial]. ( Lyu, Y; Wang, LF; Yang, ZY; Zhang, HT; Zhang, X, 2019) |
| "Caffeine is effective in the treatment of apnea of prematurity." | 9.27 | Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity. ( Anderson, PJ; Asztalos, EV; Costantini, L; D'Ilario, J; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Mürner-Lavanchy, IM; Nelson, H; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2018) |
| "Caffeine therapy for apnea of prematurity did not significantly reduce the combined rate of academic, motor, and behavioral impairments but was associated with a reduced risk of motor impairment in 11-year-old children with very low birth weight." | 9.24 | Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial. ( Anderson, PJ; Asztalos, EV; Costantini, L; D'Ilario, J; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Nelson, H; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2017) |
| "To compare the efficacy and safety of standard doses of Caffeine and Aminophylline for Apnea of prematurity." | 9.24 | Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity in Preterm (≤34 weeks) Neonates: A Randomized Controlled Trial. ( Bhat Y, R; Jayashree, P; Kamath, A; Lewis, LES; Najih, M; Shashikala, -; Shivakumar, M, 2017) |
| "240 infants were randomly allocated to caffeine and aminophylline for apnea of prematurity during February 2012 to January 2015." | 9.24 | Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. ( Jayashree, P; Khurana, S; Lewis, LES; Ramesh Bhat, Y; Shivakumar, M; Sujith Kumar Reddy, GV, 2017) |
| " Caffeine is used not only for the treatment of apnea in prematurity, but also for the prevention of BPD." | 9.22 | Caffeine and bronchopulmonary dysplasia: Clinical benefits and the mechanisms involved. ( Dong, W; Lei, X; Yang, Y; Yuan, Y, 2022) |
| "Apnea of prematurity (AOP) is one of the common diseases in preterm infants." | 9.22 | [Recent research on gene polymorphisms related to caffeine therapy in preterm infants with apnea of prematurity]. ( Lin, XZ; Xie, JB, 2022) |
| "Methylxanthine, including caffeine citrate and aminophylline, is the most common pharmacologic treatment for apnea of prematurity." | 9.22 | Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis. ( Jiang, H; Li, Y; Liu, W; Miao, Y; Wang, A; Zhang, Y; Zhao, S; Zhou, Y, 2022) |
| "To determine the half-life of serum caffeine concentrations and its relation to apnea of prematurity (AOP) after caffeine is discontinued in preparation for hospital discharge." | 9.22 | Apnea of prematurity and caffeine pharmacokinetics: potential impact on hospital discharge. ( Davidson, D; DeCristofaro, J; Demeglio, D; Doyle, J; Katz, S; Varela, M, 2016) |
| "To evaluate the effectiveness and safety of different doses of caffeine in treatment of primary apnea in preterm infants." | 9.22 | [Clinical effectiveness of different doses of caffeine for primary apnea in preterm infants]. ( Liu, G; Tian, X; Zhao, Y, 2016) |
| "To investigate the effect of caffeine citrate treatment on early pulmonary function in preterm infants with apnea." | 9.22 | [Effect of caffeine citrate on early pulmonary function in preterm infants with apnea]. ( Huang, JH; Wen, XH; Wu, WY; Yu, M; Zhang, XZ; Zhu, R, 2016) |
| "It seems that preventative effects of caffeine on apnea become apparent by using the drug in very premature infants." | 9.22 | Caffeine Administration to Prevent Apnea in Very Premature Infants. ( Armanian, AM; Faghihian, E; Iranpour, R; Salehimehr, N, 2016) |
| "To evaluate the efficacy and safety of caffeine citrate in the treatment of apnea in bronchiolitis." | 9.22 | Caffeine for the Treatment of Apnea in Bronchiolitis: A Randomized Trial. ( Ahmed, W; Alansari, K; Davidson, BL; El Tatawy, LA; Khalafalla, H; Toaimah, FH, 2016) |
| "• Caffeine therapy for treatment of apnea of prematurity has been well established over the past few years." | 9.20 | High versus low-dose caffeine for apnea of prematurity: a randomized controlled trial. ( Abdel-Hady, H; Mohammed, S; Nasef, N; Nour, I; Shabaan, AE; Shouman, B, 2015) |
| "Apnea of prematurity is a common complication in premature newborns and caffeine is a widespread medication used to treat this complication." | 9.19 | The effects of caffeine on heart rate variability in newborns with apnea of prematurity. ( Blazer, S; Haleluya, NS; Ulanovsky, I; Weissman, A, 2014) |
| "To determine the effect of neonatal caffeine treatment on rates of developmental coordination disorder (DCD)." | 9.19 | Reduction in developmental coordination disorder with neonatal caffeine therapy. ( Anderson, PJ; Davis, PG; Doyle, LW; Grunau, RE; Herlenius, E; Moddemann, D; O'Brien, K; Roberts, R; Sankaran, K; Schmidt, B, 2014) |
| "Apnea of prematurity is a common condition that is usually treated with caffeine, an adenosine receptor blocker that has powerful influences on the central nervous system." | 9.19 | Long-term effects of caffeine therapy for apnea of prematurity on sleep at school age. ( Asztalos, E; Bhattacharjee, R; Biggs, SN; Bradford, R; Cheshire, M; Costantini, L; D'ilario, J; Davey, M; Dix, J; Doyle, LW; Gibbons, J; Horne, RS; Marcus, CL; Meltzer, LJ; Narang, I; Nixon, GM; Opie, G; Roberts, RS; Schmidt, B; Traylor, J, 2014) |
| "3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004." | 9.16 | Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. ( Anderson, PJ; Asztalos, EV; Barrington, KJ; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2012) |
| "To compare standard doses of theophylline and caffeine for apnea of prematurity in terms of apnea frequency and assess the need for therapeutic drug monitoring." | 9.14 | Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. ( Bacopoulou, F; Markantonis, SL; Skouroliakou, M, 2009) |
| "To determine whether the benefits of caffeine vary in three subgroups of 2006 participants in the Caffeine for Apnea of Prematurity (CAP) trial." | 9.14 | Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. ( Asztalos, E; Davis, PG; Doyle, LW; Haslam, R; Roberts, RS; Schmidt, B; Sinha, S; Tin, W, 2010) |
| "The objective of this study was to develop a population model of the pharmacokinetics (PK) of caffeine after orogastric or intravenous administration to extremely premature neonates with apnea of prematurity who were to undergo extubation from ventilation." | 9.13 | Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring. ( Charles, BG; Flenady, VJ; Gray, PH; Shearman, A; Steer, PA; Townsend, SR, 2008) |
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g during the first 10 days of life to receive either caffeine or placebo, until drug therapy for apnea of prematurity was no longer needed." | 9.12 | Caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2006) |
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed." | 9.12 | Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007) |
| "Fourteen preterm newborns born at 24 to 28 gestational weeks presenting recurrent apnea despite caffeine and doxapram therapy were exposed to a pleasant odor diffused during 24 hours in the incubator." | 9.11 | Olfactory stimulation prevents apnea in premature newborns. ( Gaugler, C; Marlier, L; Messer, J, 2005) |
| "Fifteen infants, median gestational age at birth 27 weeks (range 24-30), age at study 27 days (12-60), with >/=6 episodes of bradycardia or hypoxaemia/6 h despite serum caffeine levels in the therapeutic range, received doxapram either intravenously (0." | 9.09 | Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants. ( Bohnhorst, B; Darraj, S; Poets, CF, 1999) |
| "To evaluate the efficacy and safety of caffeine citrate for treatment of apnea of prematurity." | 9.09 | Caffeine citrate for the treatment of apnea of prematurity: a double-blind, placebo-controlled study. ( Erenberg, A; Haack, DG; Hicks, GM; Leff, RD; Mosdell, KW; Wynne, BA, 2000) |
| " Aminophylline (n = 98) and caffeine citrate (n = 82) were equally effective in preventing apnea and bradycardia." | 9.08 | Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates. ( Brendstrup, L; Flachs, H; Larsen, PB; Skov, L, 1995) |
| "Caffeine is a potentially useful alternative to theophylline for the treatment and prevention of apnea of prematurity because of its lower toxicity and longer terminal half-life." | 9.08 | Saliva as a valid alternative to serum in monitoring intravenous caffeine treatment for apnea of prematurity. ( Charles, BG; Flenady, VJ; Lee, TC; Steer, PA, 1996) |
| "The study the population pharmacokinetics of caffeine after intravenous administration to premature infants with apnea." | 9.08 | Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. ( Charles, B; Flenady, V; Lee, TC; Shearman, A; Steer, P, 1997) |
| " Tracings were analyzed for evidence of apnea, periodic breathing, and/or bradycardia by a pulmonologist unaware of the drug given." | 9.06 | High-dose caffeine suppresses postoperative apnea in former preterm infants. ( Fink, R; Hannallah, RS; Hicks, JM; Ruttimann, UE; Welborn, LG, 1989) |
| "Apnea remains one of the most concerning and prevalent respiratory disorders spanning all ages from infants (particularly those born preterm) to adults." | 9.05 | Mechanistic actions of oxygen and methylxanthines on respiratory neural control and for the treatment of neonatal apnea. ( MacFarlane, PM; Mitchell, L, 2020) |
| " The effectiveness of caffeine with regard to treatment success and the rate of apnea was not significantly different from that of theophylline or doxapram in two SRMAs." | 9.05 | Caffeine for the Treatment of Apnea in the Neonatal Intensive Care Unit: A Systematic Overview of Meta-Analyses. ( Abushanab, D; Al-Badriyeh, D; Al-Shaibi, S; Alhersh, E, 2020) |
| "This prospective controlled study was aimed at evaluating the efficacy of caffeine in treating recurrent idiopathic apnea in the premature infant." | 9.05 | The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants. ( Blin, MC; Couchard, M; De Gamarra, E; Dreyfus-Brisac, C; Flouvat, B; Moriette, G; Murat, I; Relier, JP, 1981) |
| "The purpose of our prospective randomized study was to compare the efficacy of theophylline ethylenediamine and caffeine sodium citrate in the treatment of idiopathic apnea in premature infants." | 9.05 | Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. ( Brouard, C; de Gamarra, E; Flouvat, B; Moriette, G; Murat, I; Pajot, N; Relier, JP; Walti, H, 1985) |
| "Caffeine is widely used for the treatment of neonatal apnea, but there is no agreement on the optimum maintenance dose for preterm infants." | 8.98 | Efficacy and Safety of Different Maintenance Doses of Caffeine Citrate for Treatment of Apnea in Premature Infants: A Systematic Review and Meta-Analysis. ( Chen, J; Chen, X; Jin, L, 2018) |
| "The randomized controlled trials showed less apnea during doxapram treatment when compared to placebo, but no difference in treatment effect when compared to theophylline." | 8.95 | Doxapram Treatment for Apnea of Prematurity: A Systematic Review. ( Onland, W; Ten Hove, CH; van Kaam, AH; Vliegenthart, RJ, 2017) |
| "Caffeine is a methylxanthine that is widely used to treat apnea of prematurity (AOP)." | 8.95 | Caffeine for apnea of prematurity: Effects on the developing brain. ( Atik, A; Cheong, J; De Matteo, R; Doyle, LW; Harding, R; Kondos-Devcic, D; Tolcos, M, 2017) |
| "The respiratory stimulant caffeine is the most frequently used xanthine (theophylline or aminophylline) for the treatment of apnea in premature infants." | 8.91 | An Overview on the Respiratory Stimulant Effects of Caffeine and Progesterone on Response to Hypoxia and Apnea Frequency in Developing Rats. ( Bairam, A; Joseph, V; Mubayed, S; Uppari, N, 2015) |
| "Apnea of prematurity (AOP) is a common complication of preterm birth, which affects more than 80 % of neonates with a birth weight less than 1,000 g." | 8.90 | Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity. ( Schoen, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Yu, T, 2014) |
| " It is thanks to the efforts of Barbara Schmidt and the Caffeine for Apnea of Prematurity (CAP) Trial Group that we now have high-quality and reliable data not only on short-term but also long-term outcomes of caffeine use for apnea of prematurity." | 8.90 | Caffeine for apnea of prematurity: a neonatal success story. ( Bassler, D; Kreutzer, K, 2014) |
| "Apnea of prematurity (AOP) is a significant clinical problem manifested by an unstable respiratory rhythm reflecting the immaturity of respiratory control systems." | 8.87 | Apnea of prematurity: pathogenesis and management strategies. ( Mathew, OP, 2011) |
| "Prematurity apnea remains a major clinical problem that requires treatment choices which are sometimes difficult." | 8.86 | [Apnea of prematurity: what's new?]. ( El Ayoubi, M; Lescure, S; Lopez, E; Moriette, G, 2010) |
| "To evaluate the effect of caffeine compared with theophylline treatment on the risk of apnea and use of mechanical ventilation in preterm infants with recurrent apnea." | 8.86 | Caffeine versus theophylline for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, PA, 2010) |
| " The diagnosis of apnea of prematurity (AOP) is one of exclusion." | 8.82 | Treatment of apnea of prematurity. ( Bhatt-Mehta, V; Schumacher, RE, 2003) |
| "All trials utilizing random or quasi-random patient allocation, in which methylxanthine (theophylline or caffeine) was compared with placebo or no treatment for apnea in preterm infants, were included." | 8.81 | Methylxanthine treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2001) |
| "Apnea, defined as cessation of breathing resulting in pathological changes in heart rate and oxygen saturation, is a common occurrence in sick neonates." | 8.81 | Apnea in the newborn. ( Aggarwal, R; Deorari, AK; Paul, VK; Singhal, A, 2001) |
| "All trials utilising random or quasi-random patient allocation, in which methylxanthine (theophylline or caffeine) was compared with placebo or no treatment for apnea in preterm infants, were included." | 8.80 | Methylxanthine treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "Apnea of prematurity (AOP) is a common problem that affects premature infants and, to a lesser degree, term infants." | 8.80 | Current options in the management of apnea of prematurity. ( Bhatia, J, 2000) |
| "Apnea of prematurity is a common problem of the premature infant under 30 weeks gestation." | 8.80 | Theophylline or caffeine: which is best for apnea of prematurity? ( Gannon, BA, 2000) |
| " Second, we recommend the use of intravenous caffeine base 10 mg/kg in all infants at risk for postoperative apnea following general anesthesia." | 8.79 | Anesthesia and apnea. Perioperative considerations in the former preterm infant. ( Greenspun, JC; Welborn, LG, 1994) |
| "Apnea of prematurity is one of the most common problems in the neonatal intensive care unit." | 8.79 | Pharmacologic management of apnea of prematurity. ( Calhoun, LK, 1996) |
| "Caffeine and theophylline are effective in the treatment of apnea in the newborn infant." | 8.76 | Methylxanthines in apnea of prematurity. ( Aranda, JV; Turmen, T, 1979) |
| " Effects of caffeine therapy for apnea of prematurity on sleep and neurodevelopment of preterm infants at 6 months of corrected age." | 8.31 | Effects of caffeine therapy for apnea of prematurity on sleep and neurodevelopment of preterm infants at 6 months of corrected age. ( Akdere, SK; Atalah, YEY; Barış, HE; Boran, P; Eralp, EE; Gücüyener, K; Özdemir, H; Özek, E; Sabancı, M, 2023) |
| "Central apnea is a major cause of death in neonates with trisomy 18 (T18) and is likely due to immaturity of the respiratory drive, similar to the pathological mechanism in apnea of prematurity." | 8.12 | Caffeine for the Treatment of Central Apnea in Trisomy 18: A Case Study in the Novel Use of Methylxanthines in Palliative Transport. ( Andersen, L; Ariagno, S; Collura, C; Thorvilson, M, 2022) |
| "The purpose of this paper is to verify whether the concentrations of caffeine in saliva are comparable to serum concentrations in preterm infants who are treated with caffeine for apnea of prematurity." | 8.12 | The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity. ( Andrés, JLP; Cañada-Martínez, AJ; García-Robles, A; González, PS; Pericás, CC; Ponce-Rodriguez, HD; Solaz-García, Á; Vento, M; Verdú-Andrés, J, 2022) |
| "Caffeine citrate is the most frequently used medication in preterm neonates for the prevention of apnea of prematurity." | 8.02 | Caffeine citrate for apnea of prematurity-One dose does not fit all a prospective study. ( Gueta, I; Hanna, M; Loebstein, R; Rosen, C; Strauss, T; Taran, C; Yarden-Bilavsky, H, 2021) |
| "Apnea is commonly encountered in children with bronchiolitis." | 7.96 | Caffeine treatment for bronchiolitis-related apnea in the pediatric intensive care unit. ( Brossier, D; Denis, M; Faucon, C; Goyer, I; Heuzé, N; Jokic, M; Porcheret, F, 2020) |
| "Caffeine citrate is a commonly used methylxanthine for pharmacologic treatment of apnea of prematurity." | 7.96 | Population pharmacokinetic study of caffeine citrate in Chinese premature infants with apnea. ( Di, X; Fan, J; Guo, A; Hu, X; Huang, L; Xie, H; Xue, J; Zhao, P; Zhu, Z, 2020) |
| " Methylxanthine is widely administered for the treatment of apnea of prematurity in many countries, and previous reports have clearly established that caffeine is effective for the treatment of apnea of prematurity." | 7.88 | [Comparative Study of the Efficacy and Safety of Caffeine and Aminophylline for the Treatment of Apnea in Preterm Infants]. ( Kamimura, H; Nagasato, A; Nakamura, M, 2018) |
| "This study explored the feasibility effect and safety of the limb stimulation (LS) for the treatment of neonatal apnea (NAP)." | 7.88 | A pilot study of limb stimulation for the treatment of neonatal apnea. ( Dong, LB; Li, YF; Qiao, S; Zhang, Y, 2018) |
| "To study the clinical effect of early or late administration of caffeine citrate in the prevention and treatment of apnea in very low birth weight (VLBW) infants." | 7.88 | [Clinical effect of early or late administration of caffeine citrate in prevention and treatment of apnea in very low birth weight infants]. ( Chen, X; Cheng, R; Feng, Y; Mao, XN; Qiu, J; Zhao, L, 2018) |
| "Incidence fell from 74% diagnosed with apnea of prematurity at baseline to 49% diagnosed with CSCPE postimplementation (P<0." | 7.85 | Clinically significant cardiopulmonary events and the effect of definition standardization on apnea of prematurity management. ( Ahlers-Schmidt, CR; Bloom, BT; Engel, M; Powell, MB, 2017) |
| "Apnea of prematurity affects a small proportion but large absolute number of late preterm infants, with out-patient management variably utilized despite relative clinical equipoise and potential for improved cost-effectiveness." | 7.85 | Economics of Home Monitoring for Apnea in Late Preterm Infants. ( Amberson, M; Dukhovny, D; Freiberger, C; Montenegro, BL; Rhein, LM; Veit, L, 2017) |
| "Apnea of prematurity (AOP) is nearly universal among very preterm infants, but neither the apnea burden nor its clinical associations have been systematically studied in a large consecutive cohort." | 7.83 | Clinical associations of immature breathing in preterm infants: part 1-central apnea. ( Delos, J; Fairchild, K; Kattwinkel, J; Lake, D; Mohr, M; Moorman, JR; Paget-Brown, A; Tabacaru, C, 2016) |
| " Those in the center of the co-existent knowledge map of Chinses keywords were "preterm infants", "apnea", "primary apnea", "naloxone" and "aminophylline"; while "apnea", "preterm infants" and "caffeine" located in the central place of the co-existent knowledge map of English keywords." | 7.83 | [Current research status of drug therapy for apnea of prematurity]. ( Chen, C; Mu, DZ; Shi, J; Shu, XX; Tang, J; Yang, XY, 2016) |
| "Caffeine, standard treatment for apnea of prematurity, improves brainstem auditory processing." | 7.81 | Effects of caffeine treatment for apnea of prematurity on cortical speech-sound differentiation in preterm infants. ( Aschner, JL; Chan, J; Key, AP; Lambert, WE; Maitre, NL; Stark, AR, 2015) |
| "Apnea is nearly universal among very low birth weight (VLBW) infants, and the associated bradycardia and desaturation may have detrimental consequences." | 7.81 | Very long apnea events in preterm infants. ( Clark, MT; Delos, JB; Fairchild, KD; Kattwinkel, J; Lake, DE; Lee, H; Mennen, AC; Mohr, MA; Moorman, JR; Sinkin, RA; Vergales, BD, 2015) |
| "Apnea of prematurity, which is prevalent among infants born at less than 34 weeks gestation, is treated with caffeine, theophylline, or aminophylline." | 7.81 | Ampakines enhance weak endogenous respiratory drive and alleviate apnea in perinatal rats. ( Ding, X; Greer, JJ; Ren, J, 2015) |
| " We prospectively compared the safety profile of ECC and LP in preterm infants with apnea of prematurity." | 7.80 | Safety profile comparison between extemporaneous and a licensed preparation of caffeine citrate in preterm infants with apnea of prematurity. ( Arand, J; Engel, C; Poets, CF; Vatlach, S, 2014) |
| "Apnea of prematurity, a common disorder, can severely compromise an infant's condition unless correctly diagnosed and treated." | 7.80 | Standardizing documentation and the clinical approach to apnea of prematurity reduces length of stay, improves staff satisfaction, and decreases hospital cost. ( Butler, TJ; Firestone, KS; Grow, JL; Kantak, AD, 2014) |
| "To investigate the clinical efficacy and safety of caffeine citrate and aminophylline in the treatment of primary apnea in premature infants." | 7.80 | [Comparison of caffeine citrate and aminophylline for treating primary apnea in premature infants]. ( Chen, DM; Wang, RQ; Xu, JL, 2014) |
| " Indications for caffeine use in that study were predominantly for treatment of apnea and facilitation of extubation rather than prophylaxis." | 7.79 | Methylxanthine use for apnea of prematurity among an international cohort of neonatologists. ( Abu Jawdeh, EG; Argus, BM; Bandyopadhyay, A; Davis, PG; Limrungsikul, A; Martin, RJ; Nakad, PE; O'Riordan, M; Supapannachart, S; Yunis, KA, 2013) |
| "To determine the cost-effectiveness of treatment with caffeine compared with placebo for apnea of prematurity in infants with birth weights less than 1250 g, from birth through 18 to 21 months' corrected age." | 7.77 | Economic evaluation of caffeine for apnea of prematurity. ( Doyle, LW; Dukhovny, D; Kamholz, KL; Kok, JH; Lorch, SA; Mao, W; Roberts, RS; Schmidt, B; Wang, N; Zupancic, JA, 2011) |
| "The mechanisms underlying the therapeutic function of caffeine on apneas in preterm neonates are not well determined." | 7.76 | Caffeine reduces apnea frequency and enhances ventilatory long-term facilitation in rat pups raised in chronic intermittent hypoxia. ( Bairam, A; Joseph, V; Julien, CA, 2010) |
| "Caffeine is a common treatment for apnea of prematurity." | 7.75 | Enhancement of the breathing frequency response to hypoxia by neonatal caffeine treatment in adult male rats: the role of testosterone. ( Bairam, A; Joseph, V; Kinkead, R; Lajeunesse, Y; Montandon, G, 2009) |
| "Caffeine is an adenosine receptor antagonist commonly used as a respiratory stimulant to treat neonatal apneas of premature newborn." | 7.73 | Long-term consequences of neonatal caffeine on ventilation, occurrence of apneas, and hypercapnic chemoreflex in male and female rats. ( Bairam, A; Kinkead, R; Montandon, G, 2006) |
| "Caffeine citrate is commonly used for prophylaxis and treatment of apnea in preterm babies." | 7.73 | [Caffeine citrate utilization for treatment of apnea in French neonatal units]. ( Baudon, JJ; Biran-Mucignat, V; Ducrocq, S; Gold, F; Lebas, F, 2006) |
| "Apnea of prematurity develop during the first days of life and usually resolve by the time the infant reaches 36-37 weeks postmenstrual age." | 7.73 | [Apnea of prematurity: risk factors and ambulatory treatment with caffeine citrate]. ( Baudon, JJ; Biran-Mucignat, V; Boelle, PY; Ducrocq, S; Gold, F; Lebas, F, 2006) |
| " This study evaluates the effect of caffeine on oxygen consumption and metabolic rate in premature infants with idiopathic apnea." | 7.71 | Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. ( Bauer, J; Hentschel, R; Linderkamp, O; Maier, K, 2001) |
| "To report the occurrence of apnea and bradycardia in two former pre-term infants who received spinal anaesthesia without inhalational or intravenous anaesthetic agents during inguinal herniorrhaphy." | 7.70 | Apnea following spinal anaesthesia in two former pre-term infants. ( Burd, RS; Helikson, MA; Tobias, JD, 1998) |
| "A retrospective review was done to identify infants who received caffeine therapy for RSV-associated apnea." | 7.70 | Caffeine in the treatment of apnea associated with respiratory syncytial virus infection in neonates and infants. ( Tobias, JD, 2000) |
| "To determine whether predischarge event recording (PDER) can accurately identify preterm infants with resolving apnea of prematurity (AOP) at risk for postdischarge complications." | 7.70 | Prediction of postdischarge complications by predischarge event recordings in infants with apnea of prematurity. ( DeCristofaro, JD; Katz, S; Subhani, M, 2000) |
| "Apnea of prematurity is a common problem in neonatal intensive care nurseries." | 7.68 | Plasma beta-endorphin concentration and xanthine treatment in apnea of prematurity. ( Hindmarsh, KW; Kalapurackal, M; Sankaran, K; Tan, L, 1993) |
| "The effectiveness of caffeine citrate in preventing idiopathic apnea in premature infants was evaluated." | 7.68 | Effectiveness and side effects of two different doses of caffeine in preventing apnea in premature infants. ( Carnevale, A; Chiarotti, M; De Carolis, MP; De Giovanni, N; Muzii, U; Romagnoli, C; Tortorolo, G; Zecca, E, 1992) |
| "The simultaneous determination of caffeine and theophylline plasmatic levels has been proposed when the later is used in the treatment of the newborn's apnea." | 7.68 | [Importance of monitoring theophylline and caffeine plasma levels in the management of neonatal apnea]. ( Sacristán del Castillo, JA; Soto Alvarez, J, 1991) |
| " Comparison of the groups using quantitative measures of apnea, bradycardia, and periodic breathing obtained from pneumogram analysis and the incidence of monitor alarms on bedside nursing records showed no significant differences." | 7.67 | Transplacentally acquired caffeine and the occurrence of apnea, bradycardia, and periodic breathing in preterm infants: preliminary communication. ( Braun, RJ; Evans, MA; Kelly, DH; McCulloch, KM; Simms, PE, 1989) |
| "Theophylline and caffeine are two xanthine-derivated drugs frequently administered for their stimulating effects on the respiratory center in premature babies presenting with "idiopathic apnea"." | 7.67 | [Xanthines in apnea of premature infants. Influence on gastroesophageal reflux]. ( Sacré, L; Vandenplas, Y, 1987) |
| "This review provides an understanding of current problems related to apnea of infancy." | 7.67 | Infant apnea. ( Fox, WW; Spitzer, AR, 1986) |
| "To evaluate the relationship of antecedent maternal smoking and caffeine consumption habits on the occurrence of apnea in their offspring, rates for central and obstructive apnea were analyzed in a cohort of mother-infant pairs." | 7.67 | Effects of maternal smoking and caffeine habits on infantile apnea: a retrospective study. ( Bendell, D; Duke, JC; Mattice, CD; McCaffree, MA; Orr, WC; Toubas, PL, 1986) |
| " Because caffeine is a respiratory stimulant, its effect on breathing pattern was evaluated in 12 infants with infantile apnea." | 7.66 | Effect of caffeine on control of breathing in infantile apnea. ( Aranda, JV; Davis, J; Grondin, D; Trippenbach, T; Turmen, T; Watters, G; Zinman, R, 1983) |
| "The interactive effect of caffeine and continuous distending airway pressure was evaluated in two premature neonates with apnea." | 7.66 | Interaction of caffeine and continuous distending airway pressure in neonatal apnea. ( Aranda, JV; Outerbridge, EW; Trippenbach, T, 1983) |
| " Treatment of neonatal apnea with theophylline as documented by a normal follow-up pneumocardiogram should be considered successful only when the levels of both theophylline and caffeine have been documented subtherapeutic at time of re-test." | 7.66 | Effect of serum caffeine level on pneumocardiogram of premature infants treated for apnea with theophylline. ( Banagale, RC, 1982) |
| "Theophylline and caffeine are both effective stimulants of the central nervous system for the therapy of neonatal apnea." | 7.66 | Pharmacologic considerations in the therapy of neonatal apnea. ( Aranda, JV; Grondin, D; Sasyniuk, BI, 1981) |
| "Growth, neurologic, and ophthalmologic assessments were done in 21 low-birth-weight infants given caffeine for neonatal apnea and in 21 matched control infants." | 7.66 | Sequelae of caffeine treatment in preterm infants with apnea. ( Aranda, JV; Gunn, TR; Metrakos, K; Riley, P; Willis, D, 1979) |
| "The pharmacokinetic profile of caffeine was studied in 32 premature newborn infants with apnea: 12 following a single intravenous dose; 3 after a single oral dose; 7 during treatment with an initial empirical (high) maintenance dose schedule; and 10 during treatment with a revised (lower) dose schedule." | 7.66 | Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. ( Aldridge, A; Aranda, JV; Collinge, JM; Cook, CE; Gorman, W; Loughnan, PM; Neims, AH; Outerbridge, EW, 1979) |
| "The efficacy of caffeine citrate in the management of apnea in the newborn infant was evaluated." | 7.65 | Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. ( Aranda, JV; Bergsteinsson, H; Gorman, W; Gunn, T, 1977) |
| " The aims of this study were to develop and evaluate population pharmacokinetic (PPK) models of caffeine in preterm infants through comprehensive screening of covariates and then to propose model-informed precision dosing of caffeine for this population." | 5.72 | Population pharmacokinetic modeling of caffeine in preterm infants with apnea of prematurity: New findings from concomitant erythromycin and AHR genetic polymorphisms. ( Chen, F; Cheng, R; Dai, HR; Ding, XS; Guo, HL; He, X; Hu, YH; Jiao, Z; Liu, Y; Lu, KY; Xu, J, 2022) |
| "Caffeine is commonly used to prevent or treat apnea in preterm neonates." | 5.51 | Effect of Prophylactic Caffeine on Noninvasive Respiratory Support in Preterm Neonates Weighing 1250-2000 g: A Randomized Controlled Trial. ( Armanian, AM; Feizi, A; Iranpour, R; Miladi, N, 2022) |
| "In a randomized controlled trial including preterm infants < 32 weeks' gestation, prophylactic (in the first 72 h of life) versus therapeutic (only if apnea exists or infant requires mechanical ventilation) decision of caffeine was compared." | 5.51 | Prophylactic versus therapeutic caffeine for apnea of prematurity: a randomized controlled trial. ( Elmowafi, M; Mohsen, N; Nasef, N; Nour, I, 2022) |
| " Caffeine is widely used to prevent and treat apnea (temporal cessation of breathing) associated with prematurity and facilitate extubation." | 5.41 | Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity. ( Brattström, P; Bruschettini, M; Davis, PG; Onland, W; Russo, C; Soll, R, 2023) |
| "Methylxanthines, including caffeine, theophylline, and aminophylline, work as stimulants of the respiratory drive, and decrease apnea of prematurity, a developmental disorder common in preterm infants." | 5.41 | Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants. ( Bruschettini, M; Marques, KA; Moresco, L; Sjögren, A; Soll, R, 2023) |
| "To evaluate the benefits and harms of doxapram administration on the incidence of apnea and other short-term and longer-term clinical outcomes in preterm infants." | 5.41 | Doxapram for the prevention and treatment of apnea in preterm infants. ( Avdic, E; Bruschettini, M; Evans, S; Fiander, M; Pessano, S; Soll, R, 2023) |
| " Although methylxanthines are widely used to prevent and treat apnea associated with prematurity and to facilitate extubation, there is uncertainty about the benefits and harms of different types of methylxanthines." | 5.41 | Methylxanthine for the prevention and treatment of apnea in preterm infants. ( Bruschettini, M; Davis, PG; Fiander, M; Marques, KA; Roehr, CC; Soll, R, 2023) |
| "There is sufficient evidence to support use of caffeine therapy for apnea of prematurity, but practices vary widely when it comes to discontinuing therapy." | 5.41 | Duration of Caffeine for Apnea of Prematurity-A Randomized Controlled Trial. ( Jain, N; Nair, PMC; Nandakumar, A; Pournami, F; Prabhakar, J; Prakash, R, 2021) |
| "To compare the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants." | 5.34 | [Comparison of the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants: a prospective randomized double-blind controlled trial]. ( Ding, Y; Gan, JM; He, T; Li, W; Liao, ZC; Wang, MJ; Yue, SJ, 2020) |
| " There were fewer instances of apnea of prematurity and shorter assisted ventilation times for infants in the caffeine group compared to the placebo group (p < 0." | 5.34 | Early application of caffeine improves white matter development in very preterm infants. ( Liu, S; Liu, Y; Wang, X; Xu, F; Yang, L; Yuan, X; Zhang, R; Zhang, X; Zhu, C, 2020) |
| "Preterm infants with apnea who were born at less than 32 weeks of gestational age and birth weight ≤1500 g were randomly divided into caffeine citrate prevention group and caffeine citrate treatment group." | 5.34 | Influence of prevention of caffeine citrate on cytokine profile and bronchopulmonary dysplasia in preterm infants with apnea. ( Gao, Z; Han, D; Kou, C; Li, Z; Liu, Z; Wu, W; Zhang, Y, 2020) |
| "The study was performed using information on echocardiography measurements from preterm neonates recruited for apnea of prematurity (75 of 240) and preventing extubation failure (113 of 156) studies." | 5.30 | Acute hemodynamic effects of methylxanthine therapy in preterm neonates: Effect of variations in subgroups. ( Kamath, A; Lewis, LES; M, S; Nayak, K; Purkayastha, J, 2019) |
| "Caffeine is effective in the treatment of apnea of prematurity." | 5.27 | Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity. ( Anderson, PJ; Asztalos, EV; Costantini, L; D'Ilario, J; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Mürner-Lavanchy, IM; Nelson, H; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2018) |
| "Caffeine half-life was greatly increased in two infants who had cholestatic hepatitis secondary to prolonged parenteral alimentation and one infant who was breast-fed exclusively." | 5.27 | Maturational changes of caffeine concentrations and disposition in infancy during maintenance therapy for apnea of prematurity: influence of gestational age, hepatic disease, and breast-feeding. ( Billon, B; Le Guennec, JC; Paré, C, 1985) |
| " The mean plasma half-live of theophylline was 22." | 5.26 | [Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ( Lipowsky, G; Riechert, M; Stiegler, H; Stöckl, H, 1981) |
| "Caffeine therapy for apnea of prematurity did not significantly reduce the combined rate of academic, motor, and behavioral impairments but was associated with a reduced risk of motor impairment in 11-year-old children with very low birth weight." | 5.24 | Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial. ( Anderson, PJ; Asztalos, EV; Costantini, L; D'Ilario, J; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Nelson, H; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2017) |
| "To compare the efficacy and safety of standard doses of Caffeine and Aminophylline for Apnea of prematurity." | 5.24 | Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity in Preterm (≤34 weeks) Neonates: A Randomized Controlled Trial. ( Bhat Y, R; Jayashree, P; Kamath, A; Lewis, LES; Najih, M; Shashikala, -; Shivakumar, M, 2017) |
| "240 infants were randomly allocated to caffeine and aminophylline for apnea of prematurity during February 2012 to January 2015." | 5.24 | Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity. ( Jayashree, P; Khurana, S; Lewis, LES; Ramesh Bhat, Y; Shivakumar, M; Sujith Kumar Reddy, GV, 2017) |
| " Caffeine is used not only for the treatment of apnea in prematurity, but also for the prevention of BPD." | 5.22 | Caffeine and bronchopulmonary dysplasia: Clinical benefits and the mechanisms involved. ( Dong, W; Lei, X; Yang, Y; Yuan, Y, 2022) |
| "Apnea of prematurity is a developmental disorder affecting most extremely preterm infants." | 5.22 | Caffeine: Some of the Evidence behind Its Use and Abuse in the Preterm Infant. ( Bancalari, E; Chavez, L, 2022) |
| "Apnea of prematurity (AOP) is one of the common diseases in preterm infants." | 5.22 | [Recent research on gene polymorphisms related to caffeine therapy in preterm infants with apnea of prematurity]. ( Lin, XZ; Xie, JB, 2022) |
| "Methylxanthine, including caffeine citrate and aminophylline, is the most common pharmacologic treatment for apnea of prematurity." | 5.22 | Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis. ( Jiang, H; Li, Y; Liu, W; Miao, Y; Wang, A; Zhang, Y; Zhao, S; Zhou, Y, 2022) |
| "To determine the half-life of serum caffeine concentrations and its relation to apnea of prematurity (AOP) after caffeine is discontinued in preparation for hospital discharge." | 5.22 | Apnea of prematurity and caffeine pharmacokinetics: potential impact on hospital discharge. ( Davidson, D; DeCristofaro, J; Demeglio, D; Doyle, J; Katz, S; Varela, M, 2016) |
| "To evaluate the effectiveness and safety of different doses of caffeine in treatment of primary apnea in preterm infants." | 5.22 | [Clinical effectiveness of different doses of caffeine for primary apnea in preterm infants]. ( Liu, G; Tian, X; Zhao, Y, 2016) |
| "To investigate the effect of caffeine citrate treatment on early pulmonary function in preterm infants with apnea." | 5.22 | [Effect of caffeine citrate on early pulmonary function in preterm infants with apnea]. ( Huang, JH; Wen, XH; Wu, WY; Yu, M; Zhang, XZ; Zhu, R, 2016) |
| "It seems that preventative effects of caffeine on apnea become apparent by using the drug in very premature infants." | 5.22 | Caffeine Administration to Prevent Apnea in Very Premature Infants. ( Armanian, AM; Faghihian, E; Iranpour, R; Salehimehr, N, 2016) |
| "To evaluate the efficacy and safety of caffeine citrate in the treatment of apnea in bronchiolitis." | 5.22 | Caffeine for the Treatment of Apnea in Bronchiolitis: A Randomized Trial. ( Ahmed, W; Alansari, K; Davidson, BL; El Tatawy, LA; Khalafalla, H; Toaimah, FH, 2016) |
| "Early caffeine treatment can reduce the need for assisted ventilation in preterm infants with RDS, help with early extubation and ventilator weaning, reduce the oxygen time in the late stage, reduce the incidence of VAP, and prevent the development of apnea after extubation." | 5.22 | [Effect of early caffeine treatment on the need for respirator therapy in preterm infants with respiratory distress syndrome]. ( Duan, YH; Han, JT; Su, P; Wei, QZ; Zhang, X, 2016) |
| "• Caffeine therapy for treatment of apnea of prematurity has been well established over the past few years." | 5.20 | High versus low-dose caffeine for apnea of prematurity: a randomized controlled trial. ( Abdel-Hady, H; Mohammed, S; Nasef, N; Nour, I; Shabaan, AE; Shouman, B, 2015) |
| "Apnea of prematurity is a common complication in premature newborns and caffeine is a widespread medication used to treat this complication." | 5.19 | The effects of caffeine on heart rate variability in newborns with apnea of prematurity. ( Blazer, S; Haleluya, NS; Ulanovsky, I; Weissman, A, 2014) |
| "To determine the effect of neonatal caffeine treatment on rates of developmental coordination disorder (DCD)." | 5.19 | Reduction in developmental coordination disorder with neonatal caffeine therapy. ( Anderson, PJ; Davis, PG; Doyle, LW; Grunau, RE; Herlenius, E; Moddemann, D; O'Brien, K; Roberts, R; Sankaran, K; Schmidt, B, 2014) |
| "Apnea of prematurity is a common condition that is usually treated with caffeine, an adenosine receptor blocker that has powerful influences on the central nervous system." | 5.19 | Long-term effects of caffeine therapy for apnea of prematurity on sleep at school age. ( Asztalos, E; Bhattacharjee, R; Biggs, SN; Bradford, R; Cheshire, M; Costantini, L; D'ilario, J; Davey, M; Dix, J; Doyle, LW; Gibbons, J; Horne, RS; Marcus, CL; Meltzer, LJ; Narang, I; Nixon, GM; Opie, G; Roberts, RS; Schmidt, B; Traylor, J, 2014) |
| "3%) had been enrolled in the randomized, placebo-controlled Caffeine for Apnea of Prematurity trial between 1999 and 2004." | 5.16 | Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. ( Anderson, PJ; Asztalos, EV; Barrington, KJ; Davis, PG; Dewey, D; Doyle, LW; Grunau, RE; Moddemann, D; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2012) |
| "To compare standard doses of theophylline and caffeine for apnea of prematurity in terms of apnea frequency and assess the need for therapeutic drug monitoring." | 5.14 | Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. ( Bacopoulou, F; Markantonis, SL; Skouroliakou, M, 2009) |
| "To determine whether the benefits of caffeine vary in three subgroups of 2006 participants in the Caffeine for Apnea of Prematurity (CAP) trial." | 5.14 | Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. ( Asztalos, E; Davis, PG; Doyle, LW; Haslam, R; Roberts, RS; Schmidt, B; Sinha, S; Tin, W, 2010) |
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g during the first 10 days of life to receive either caffeine or placebo, until drug therapy for apnea of prematurity was no longer needed." | 5.12 | Caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2006) |
| "We randomly assigned 2006 infants with birth weights of 500 to 1250 g to receive either caffeine or placebo until therapy for apnea of prematurity was no longer needed." | 5.12 | Long-term effects of caffeine therapy for apnea of prematurity. ( Barrington, KJ; Davis, P; Doyle, LW; Ohlsson, A; Roberts, RS; Schmidt, B; Solimano, A; Tin, W, 2007) |
| "Fourteen preterm newborns born at 24 to 28 gestational weeks presenting recurrent apnea despite caffeine and doxapram therapy were exposed to a pleasant odor diffused during 24 hours in the incubator." | 5.11 | Olfactory stimulation prevents apnea in premature newborns. ( Gaugler, C; Marlier, L; Messer, J, 2005) |
| "Monohydrated caffeine was the only respiratory xanthine available in our country to treat apnea of premature infant." | 5.10 | [Pharmacologic study of monohydrated caffeine in the treatment of apnoea of premature infant]. ( Belkahia, C; Boukef-Larguèche, S; Chaouachi, S; Cherif, A; Klouz, A; Marrakchi, Z, 2003) |
| "Fifteen infants, median gestational age at birth 27 weeks (range 24-30), age at study 27 days (12-60), with >/=6 episodes of bradycardia or hypoxaemia/6 h despite serum caffeine levels in the therapeutic range, received doxapram either intravenously (0." | 5.09 | Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants. ( Bohnhorst, B; Darraj, S; Poets, CF, 1999) |
| "Preterm infants with a gestational age of <32 weeks and birth weight of <1,500 g were randomized to receive either caffeine or aminophylline treatment for apnea of prematurity." | 5.09 | Brain hemodynamic changes in preterm infants after maintenance dose caffeine and aminophylline treatment. ( Bertini, G; Dani, C; Martelli, E; Reali, MF; Rubaltelli, FF; Tronchin, M; Wiechmann, L, 2000) |
| "Aminophylline and caffeine are commonly used for prophylaxis of apnea in premature infants." | 5.08 | Cerebral blood flow and left ventricular output in spontaneously breathing, newborn preterm infants treated with caffeine or aminophylline. ( Brendstrup, L; Greisen, G; Larsen, PB; Lundstrøm, KE; Skov, L, 1995) |
| " Aminophylline (n = 98) and caffeine citrate (n = 82) were equally effective in preventing apnea and bradycardia." | 5.08 | Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates. ( Brendstrup, L; Flachs, H; Larsen, PB; Skov, L, 1995) |
| " Tracings were analyzed for evidence of apnea, periodic breathing, and/or bradycardia by a pulmonologist unaware of the drug given." | 5.06 | High-dose caffeine suppresses postoperative apnea in former preterm infants. ( Fink, R; Hannallah, RS; Hicks, JM; Ruttimann, UE; Welborn, LG, 1989) |
| "Apnea remains one of the most concerning and prevalent respiratory disorders spanning all ages from infants (particularly those born preterm) to adults." | 5.05 | Mechanistic actions of oxygen and methylxanthines on respiratory neural control and for the treatment of neonatal apnea. ( MacFarlane, PM; Mitchell, L, 2020) |
| " The effectiveness of caffeine with regard to treatment success and the rate of apnea was not significantly different from that of theophylline or doxapram in two SRMAs." | 5.05 | Caffeine for the Treatment of Apnea in the Neonatal Intensive Care Unit: A Systematic Overview of Meta-Analyses. ( Abushanab, D; Al-Badriyeh, D; Al-Shaibi, S; Alhersh, E, 2020) |
| " In the large international Caffeine for Apnea of Prematurity trial, caffeine improved survival without neurodevelopmental disability at 18 months and demonstrated long term safety up to 11 years." | 5.05 | Neurodevelopmental outcomes after neonatal caffeine therapy. ( Grunau, RE; Synnes, A, 2020) |
| "Caffeine is an effective treatment for apnea of prematurity and has several important benefits, including decreasing respiratory morbidity and motor impairment." | 5.05 | Caffeine for preterm infants: Fixed standard dose, adjustments for age or high dose? ( Patel, RM; Saroha, V, 2020) |
| "The Caffeine for Apnea of Prematurity (CAP) trial showed that caffeine was safe when used with standard dosing and provided both pulmonary and neurological benefits to preterm infants." | 5.05 | National and international guidelines for neonatal caffeine use: Are they evidenced-based? ( Eichenwald, EC, 2020) |
| "This prospective controlled study was aimed at evaluating the efficacy of caffeine in treating recurrent idiopathic apnea in the premature infant." | 5.05 | The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants. ( Blin, MC; Couchard, M; De Gamarra, E; Dreyfus-Brisac, C; Flouvat, B; Moriette, G; Murat, I; Relier, JP, 1981) |
| "The purpose of our prospective randomized study was to compare the efficacy of theophylline ethylenediamine and caffeine sodium citrate in the treatment of idiopathic apnea in premature infants." | 5.05 | Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. ( Brouard, C; de Gamarra, E; Flouvat, B; Moriette, G; Murat, I; Pajot, N; Relier, JP; Walti, H, 1985) |
| " While robust evidence supports the use of standard doses of caffeine for apnea of prematurity or to facilitate successful extubation, much remains unknown regarding the boundaries of efficacy and safety for this common therapeutic agent." | 5.01 | Caffeine Therapy in Preterm Infants: The Dose (and Timing) Make the Medicine. ( McPherson, C; Rostas, SE, 2019) |
| "Caffeine therapy for apnea of prematurity (AOP) remains one of the pillars of neonatal care, although more evidence to support dosing and timing of initiation and discontinuation are needed." | 4.98 | Caffeine controversies. ( Carlo, WA; Gentle, SJ; Travers, CP, 2018) |
| "Placebo-controlled trials have shown that caffeine is highly effective in treating apnoea of prematurity and reduces the risk of bronchopulmonary dysplasia (BPD) and neurodevelopmental impairment (NDI)." | 4.98 | High versus standard dose caffeine for apnoea: a systematic review. ( Hutten, GJ; Miedema, M; Onland, W; van Kaam, AH; Vliegenthart, R, 2018) |
| "Apnea of prematurity (AOP) is a common and pervasive problem in very low birth weight infants." | 4.98 | Caffeine: an evidence-based success story in VLBW pharmacotherapy. ( Dobson, NR; Hunt, CE, 2018) |
| "Caffeine is widely used for the treatment of neonatal apnea, but there is no agreement on the optimum maintenance dose for preterm infants." | 4.98 | Efficacy and Safety of Different Maintenance Doses of Caffeine Citrate for Treatment of Apnea in Premature Infants: A Systematic Review and Meta-Analysis. ( Chen, J; Chen, X; Jin, L, 2018) |
| " It is used for the prevention and treatment of apnea, although this has been associated with lower incidence of bronchopulmonary dysplasia (BPD) and patent ductus arteriosus as well as intact survival at 18-21 months of life." | 4.95 | Caffeine use in the neonatal intensive care unit. ( Abu-Shaweesh, JM; Martin, RJ, 2017) |
| "The randomized controlled trials showed less apnea during doxapram treatment when compared to placebo, but no difference in treatment effect when compared to theophylline." | 4.95 | Doxapram Treatment for Apnea of Prematurity: A Systematic Review. ( Onland, W; Ten Hove, CH; van Kaam, AH; Vliegenthart, RJ, 2017) |
| " Despite aggressive respiratory support including mechanical ventilation, continuous positive airway pressure, oxygen and caffeine therapy to reduce apnea and accompanying intermittent hypoxemia, the incidence of intermittent hypoxemia events continues to increase during the first few months of life." | 4.93 | Cardiorespiratory events in preterm infants: interventions and consequences. ( Di Fiore, JM; Gauda, E; MacFarlane, P; Martin, RJ; Poets, CF, 2016) |
| " The benefits of methylxanthine-based therapies in the apnea of prematurity and their translational potential in pediatric affections of the respiratory tract are here presented." | 4.93 | The potential of methylxanthine-based therapies in pediatric respiratory tract diseases. ( Franco, R; Martínez-Pinilla, E; Oñatibia-Astibia, A, 2016) |
| "Caffeine is one of the most commonly prescribed medications in preterm neonates and is widely used to treat or prevent apnea of prematurity." | 4.93 | The Role of Caffeine in Noninvasive Respiratory Support. ( Dobson, NR; Patel, RM, 2016) |
| "The respiratory stimulant caffeine is the most frequently used xanthine (theophylline or aminophylline) for the treatment of apnea in premature infants." | 4.91 | An Overview on the Respiratory Stimulant Effects of Caffeine and Progesterone on Response to Hypoxia and Apnea Frequency in Developing Rats. ( Bairam, A; Joseph, V; Mubayed, S; Uppari, N, 2015) |
| "The use of caffeine citrate for treatment of apnea in very low birth weight infants showed short-term and long-term benefits." | 4.91 | Early Caffeine Use in Very Low Birth Weight Infants and Neonatal Outcomes: A Systematic Review and Meta-Analysis. ( Chung, S; Chung, SH; Kim, KS; Kim, SN; Lim, G; Park, HW, 2015) |
| "Apnea of prematurity (AOP) is a common complication of preterm birth, which affects more than 80 % of neonates with a birth weight less than 1,000 g." | 4.90 | Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity. ( Schoen, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Yu, T, 2014) |
| " It is thanks to the efforts of Barbara Schmidt and the Caffeine for Apnea of Prematurity (CAP) Trial Group that we now have high-quality and reliable data not only on short-term but also long-term outcomes of caffeine use for apnea of prematurity." | 4.90 | Caffeine for apnea of prematurity: a neonatal success story. ( Bassler, D; Kreutzer, K, 2014) |
| "Apnea of prematurity (AOP) is a significant clinical problem manifested by an unstable respiratory rhythm reflecting the immaturity of respiratory control systems." | 4.87 | Apnea of prematurity: pathogenesis and management strategies. ( Mathew, OP, 2011) |
| "Prematurity apnea remains a major clinical problem that requires treatment choices which are sometimes difficult." | 4.86 | [Apnea of prematurity: what's new?]. ( El Ayoubi, M; Lescure, S; Lopez, E; Moriette, G, 2010) |
| "To evaluate the effect of caffeine compared with theophylline treatment on the risk of apnea and use of mechanical ventilation in preterm infants with recurrent apnea." | 4.86 | Caffeine versus theophylline for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, PA, 2010) |
| " This ubiquitous trimethylxanthine, pervasively used in the human diet and beverages, significantly impacts on major acute neonatal morbidities including apnea of prematurity, bronchopulmonary dysplasia, patent ductus arteriousus with or without surgical ligation and post-operative apnea." | 4.86 | Caffeine impact on neonatal morbidities. ( Aranda, JV; Beharry, K; Davis, J; Natarajan, G; Valencia, GB, 2010) |
| " The diagnosis of apnea of prematurity (AOP) is one of exclusion." | 4.82 | Treatment of apnea of prematurity. ( Bhatt-Mehta, V; Schumacher, RE, 2003) |
| "All trials utilizing random or quasi-random patient allocation, in which methylxanthine (theophylline or caffeine) was compared with placebo or no treatment for apnea in preterm infants, were included." | 4.81 | Methylxanthine treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2001) |
| "Apnea, defined as cessation of breathing resulting in pathological changes in heart rate and oxygen saturation, is a common occurrence in sick neonates." | 4.81 | Apnea in the newborn. ( Aggarwal, R; Deorari, AK; Paul, VK; Singhal, A, 2001) |
| " Caffeine is used to treat apnea of the newborn because of its low toxicity." | 4.80 | Standards of laboratory practice: theophylline and caffeine monitoring. National Academy of Clinical Biochemistry. ( Kotagal, U; Pesce, AJ; Rashkin, M, 1998) |
| "All trials utilising random or quasi-random patient allocation, in which methylxanthine (theophylline or caffeine) was compared with placebo or no treatment for apnea in preterm infants, were included." | 4.80 | Methylxanthine treatment for apnea in preterm infants. ( Henderson-Smart, DJ; Steer, P, 2000) |
| "Apnea of prematurity (AOP) is a common problem that affects premature infants and, to a lesser degree, term infants." | 4.80 | Current options in the management of apnea of prematurity. ( Bhatia, J, 2000) |
| "Apnea of prematurity is a common problem of the premature infant under 30 weeks gestation." | 4.80 | Theophylline or caffeine: which is best for apnea of prematurity? ( Gannon, BA, 2000) |
| " Second, we recommend the use of intravenous caffeine base 10 mg/kg in all infants at risk for postoperative apnea following general anesthesia." | 4.79 | Anesthesia and apnea. Perioperative considerations in the former preterm infant. ( Greenspun, JC; Welborn, LG, 1994) |
| "Apnea of prematurity is one of the most common problems in the neonatal intensive care unit." | 4.79 | Pharmacologic management of apnea of prematurity. ( Calhoun, LK, 1996) |
| " Caffeine is used for the treatment of apnea of prematurity and as an additive in several analgesics and migraine remedies, and as a panacea for hyperkinetic children." | 4.77 | Caffeine: a new look at an age-old drug. ( Gupta, P; Somani, SM, 1988) |
| "Caffeine and theophylline are effective in the treatment of apnea in the newborn infant." | 4.76 | Methylxanthines in apnea of prematurity. ( Aranda, JV; Turmen, T, 1979) |
| "Caffeine is the first-choice drug for the treatment for apnea of prematurity (AOP) in preterm infants and it has been reported that it improves the diaphragm activity." | 4.31 | Effects of caffeine on diaphragmatic activity in preterm infants. ( Ciarcià, M; Corsini, I; Dani, C; Fusco, M; Gitto, E; Leonardi, V; Manti, S; Marseglia, L, 2023) |
| "Therapeutic drug monitoring is generally unnecessary in caffeine treatment for apnea of prematurity, as serum caffeine concentrations in preterm infants are normally markedly lower than those at which caffeine intoxication occurs." | 4.31 | Serum caffeine concentrations in preterm infants: a retrospective study. ( Itoh, S; Kawaguchi, N; Konishi, Y; Koyano, K; Kuboi, T; Kusaka, T; Nakamura, S; Nakano, A; Nishioka, K; Noguchi, Y; Okada, H; Sadamura, T; Sugino, M; Tadatomo, Y, 2023) |
| "In late-preterm infants, caffeine has a clear short-term respiratory stimulant effect, and it increases the arousal frequency to hypoxia." | 4.12 | Caffeine is a respiratory stimulant without effect on sleep in the short-term in late-preterm infants. ( Andersson, S; Kirjavainen, T; Seppä-Moilanen, M, 2022) |
| "Central apnea is a major cause of death in neonates with trisomy 18 (T18) and is likely due to immaturity of the respiratory drive, similar to the pathological mechanism in apnea of prematurity." | 4.12 | Caffeine for the Treatment of Central Apnea in Trisomy 18: A Case Study in the Novel Use of Methylxanthines in Palliative Transport. ( Andersen, L; Ariagno, S; Collura, C; Thorvilson, M, 2022) |
| "Caffeine has been used as a first-line drug for treatment of apnea neonatorum for decades due to its high safety and effectiveness." | 4.12 | Caffeine excites medial parabrachial nucleus neurons of mice by blocking adenosine A1 receptor. ( Cai, X; Chen, J; Gyabaah, AT; Huang, ZL; Li, Y; Li, Z; Ma, C; Shi, H; Tu, Y; Yu, C, 2022) |
| "The purpose of this paper is to verify whether the concentrations of caffeine in saliva are comparable to serum concentrations in preterm infants who are treated with caffeine for apnea of prematurity." | 4.12 | The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity. ( Andrés, JLP; Cañada-Martínez, AJ; García-Robles, A; González, PS; Pericás, CC; Ponce-Rodriguez, HD; Solaz-García, Á; Vento, M; Verdú-Andrés, J, 2022) |
| "Caffeine is available in an ampoule, used via parenteral and enteral routes in preterm neonates to treat apnea of prematurity (AOP) in neonates of gestational age ≥ 35-40 weeks." | 4.12 | Evaluation of pharmaceutically compounded oral caffeine on the impact of medication adherence and risk of readmission among preterm neonates: A single-center quasi-experimental study. ( Ali, A; Ambreen, G; Aslam, MS; Hussain, K; Kumar, M; Salat, MS; Saleem, SM; Shah, SAA; Tahir, A, 2022) |
| "Caffeine is routinely used in preterm infants for apnea of prematurity." | 4.12 | Stopping caffeine in premature neonates: how long does it take for the level of caffeine to fall below the therapeutic range? ( Aghai, ZH; Amendolia, B; Bhat, V; Chung, J; Nakhla, T; Saslow, J; Slater-Myer, L; Tran Lopez, K, 2022) |
| "Apnea of prematurity can persist despite caffeine therapy in preterm infants." | 4.02 | The Pharmacokinetics of Caffeine in Preterm Newborns: No Influence of Doxapram but Important Maturation with Age. ( Engbers, AGJ; Flint, RB; Knibbe, CAJ; Koch, BCP; Poets, CF; Reiss, IKM; Simons, SHP; Völler, S, 2021) |
| "A frequent challenge in Neonatology is the high frequency of spontaneously occurring hypoxemic events, a majority of which are associated with apnea or hypoventilation." | 4.02 | Are we over-treating hypoxic spells in preterm infants? ( Conlon, S; Di Fiore, JM; Martin, RJ, 2021) |
| "Apnea is commonly encountered in children with bronchiolitis." | 3.96 | Caffeine treatment for bronchiolitis-related apnea in the pediatric intensive care unit. ( Brossier, D; Denis, M; Faucon, C; Goyer, I; Heuzé, N; Jokic, M; Porcheret, F, 2020) |
| "Caffeine citrate is a commonly used methylxanthine for pharmacologic treatment of apnea of prematurity." | 3.96 | Population pharmacokinetic study of caffeine citrate in Chinese premature infants with apnea. ( Di, X; Fan, J; Guo, A; Hu, X; Huang, L; Xie, H; Xue, J; Zhao, P; Zhu, Z, 2020) |
| "Caffeine to prevent or treat apnea of prematurity in the newborn period is now standard of care for infants born very preterm." | 3.96 | Childhood respiratory outcomes after neonatal caffeine therapy. ( Cheong, JLY; Doyle, LW, 2020) |
| " It appears that infants with apnea of prematurity and those receiving assisted ventilation are the most likely to benefit from caffeine." | 3.96 | When to start and stop caffeine and why respiratory status matters. ( Davis, PG, 2020) |
| "Caffeine is the preferred pharmacologic treatment for apnea of prematurity." | 3.96 | Is caffeine available and affordable in low and middle-income countries? A survey in sub-Saharan Africa. ( Ayede, AI; Ekhaguere, OA; Ezeaka, CV, 2020) |
| " High doses of caffeine may produce better control of apnea." | 3.96 | Pharmacokinetics, pharmacodynamics and metabolism of caffeine in newborns. ( Aranda, JV; Beharry, KD, 2020) |
| "This study explored the feasibility effect and safety of the limb stimulation (LS) for the treatment of neonatal apnea (NAP)." | 3.88 | A pilot study of limb stimulation for the treatment of neonatal apnea. ( Dong, LB; Li, YF; Qiao, S; Zhang, Y, 2018) |
| "To study the clinical effect of early or late administration of caffeine citrate in the prevention and treatment of apnea in very low birth weight (VLBW) infants." | 3.88 | [Clinical effect of early or late administration of caffeine citrate in prevention and treatment of apnea in very low birth weight infants]. ( Chen, X; Cheng, R; Feng, Y; Mao, XN; Qiu, J; Zhao, L, 2018) |
| "Children enrolled in the CAP (Caffeine for Apnea of Prematurity) randomized controlled trial and assessed at the Royal Women's Hospital in Melbourne at 11 years of age had expiratory flow rates measured according to the standards of the American Thoracic Society." | 3.85 | Neonatal Caffeine Treatment and Respiratory Function at 11 Years in Children under 1,251 g at Birth. ( Cheong, JLY; Doyle, LW; Ranganathan, S, 2017) |
| "Incidence fell from 74% diagnosed with apnea of prematurity at baseline to 49% diagnosed with CSCPE postimplementation (P<0." | 3.85 | Clinically significant cardiopulmonary events and the effect of definition standardization on apnea of prematurity management. ( Ahlers-Schmidt, CR; Bloom, BT; Engel, M; Powell, MB, 2017) |
| "Apnea of prematurity affects a small proportion but large absolute number of late preterm infants, with out-patient management variably utilized despite relative clinical equipoise and potential for improved cost-effectiveness." | 3.85 | Economics of Home Monitoring for Apnea in Late Preterm Infants. ( Amberson, M; Dukhovny, D; Freiberger, C; Montenegro, BL; Rhein, LM; Veit, L, 2017) |
| "The pneumotach showed a linear response and clean, steady respiratory traces in which apneas and sighs were clearly visible." | 3.85 | A low cost, simplified, and scaleable pneumotachograph and face mask for neonatal mouse respiratory measurements. ( Nanu, R; Ray, RS; Sun, JJ, 2017) |
| "We recently showed that in 12-day-old male rats exposed to caffeine for 10 consecutive days, progesterone inhibits the respiratory response to hypoxia and increases apnea frequency (Uppari et al." | 3.85 | Respiratory responses to progesterone and allopregnanolone following chronic caffeine treatment in newborn female rats. ( Bairam, A; Joseph, V; Uppari, NP, 2017) |
| "Caffeine citrate is the treatment of choice for apnea of prematurity (AOP)." | 3.83 | The Real-World Routine Use of Caffeine Citrate in Preterm Infants: A European Postauthorization Safety Study. ( Carnielli, VP; Fabbri, L; Ferrari, F; Kiechl-Kohlendorfer, U; Lasagna, G; Lista, G; Papagaroufalis, K; Polackova, R; Saenz, P, 2016) |
| "Apnea of prematurity (AOP) is nearly universal among very preterm infants, but neither the apnea burden nor its clinical associations have been systematically studied in a large consecutive cohort." | 3.83 | Clinical associations of immature breathing in preterm infants: part 1-central apnea. ( Delos, J; Fairchild, K; Kattwinkel, J; Lake, D; Mohr, M; Moorman, JR; Paget-Brown, A; Tabacaru, C, 2016) |
| "Serum caffeine concentrations >20 μg/ml (100 μmol/l) in infants treated for apnea of prematurity increases TNF-α and decreases IL-10, changes that perhaps are linked to comorbidities." | 3.83 | Mechanisms of modulation of cytokine release by human cord blood monocytes exposed to high concentrations of caffeine. ( Ahlawat, R; Chavez-Valdez, R; Gauda, EB; Wills-Karp, M, 2016) |
| "A retrospective observational study was conducted in preterm neonates who received caffeine citrate therapy for apnea of prematurity and had TDM done in the post-extubation period between January 2006 and October 2011." | 3.83 | Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates. ( Balch, AH; Korgenski, EK; Sherwin, CM; Ward, RM; Yu, T, 2016) |
| " Those in the center of the co-existent knowledge map of Chinses keywords were "preterm infants", "apnea", "primary apnea", "naloxone" and "aminophylline"; while "apnea", "preterm infants" and "caffeine" located in the central place of the co-existent knowledge map of English keywords." | 3.83 | [Current research status of drug therapy for apnea of prematurity]. ( Chen, C; Mu, DZ; Shi, J; Shu, XX; Tang, J; Yang, XY, 2016) |
| " Caffeine is frequently used for apnea of prematurity." | 3.83 | Atrial arrhythmia after newborn eye exam, to caffeine or not to caffeine? ( Ahmad, A; Klein, B; Mondal, T, 2016) |
| "Advantages of caffeine for apnea of prematurity have prompted clinicians to use it prophylactically even before apnea." | 3.81 | Association of early caffeine administration and neonatal outcomes in very preterm neonates. ( Barrington, K; Lee, SK; Lodha, A; McMillan, DD; Seshia, M; Shah, PS; Yang, J, 2015) |
| "Apnea is nearly universal among very low birth weight (VLBW) infants, and the associated bradycardia and desaturation may have detrimental consequences." | 3.81 | Very long apnea events in preterm infants. ( Clark, MT; Delos, JB; Fairchild, KD; Kattwinkel, J; Lake, DE; Lee, H; Mennen, AC; Mohr, MA; Moorman, JR; Sinkin, RA; Vergales, BD, 2015) |
| "Apnea of prematurity, which is prevalent among infants born at less than 34 weeks gestation, is treated with caffeine, theophylline, or aminophylline." | 3.81 | Ampakines enhance weak endogenous respiratory drive and alleviate apnea in perinatal rats. ( Ding, X; Greer, JJ; Ren, J, 2015) |
| "Caffeine citrate is widely used to prevent and treat prematurity-associated apnea." | 3.81 | The effect of caffeine citrate on neural breathing pattern in preterm infants. ( Beck, J; Lehtonen, L; Leppäsalo, J; Parikka, V; Soukka, H; Zhai, Q, 2015) |
| "Compare how NICUs within academic centers in Canada, France, and the United States make discharge decisions regarding cardiorespiratory recordings and home use of apnea monitors, oximeters and caffeine." | 3.81 | Neonatal intensive care unit discharge of infants with cardiorespiratory events: Tri-country comparison of academic centers. ( Carlos, C; Consenstein, L; Cóté, A; Franco, P; Hageman, J; Kelly, D; McEntire, B; Pellerite, M; Raoux, A; Rusciolelli, C, 2015) |
| " We prospectively compared the safety profile of ECC and LP in preterm infants with apnea of prematurity." | 3.80 | Safety profile comparison between extemporaneous and a licensed preparation of caffeine citrate in preterm infants with apnea of prematurity. ( Arand, J; Engel, C; Poets, CF; Vatlach, S, 2014) |
| "Apnea of prematurity, a common disorder, can severely compromise an infant's condition unless correctly diagnosed and treated." | 3.80 | Standardizing documentation and the clinical approach to apnea of prematurity reduces length of stay, improves staff satisfaction, and decreases hospital cost. ( Butler, TJ; Firestone, KS; Grow, JL; Kantak, AD, 2014) |
| " Indications for caffeine use in that study were predominantly for treatment of apnea and facilitation of extubation rather than prophylaxis." | 3.79 | Methylxanthine use for apnea of prematurity among an international cohort of neonatologists. ( Abu Jawdeh, EG; Argus, BM; Bandyopadhyay, A; Davis, PG; Limrungsikul, A; Martin, RJ; Nakad, PE; O'Riordan, M; Supapannachart, S; Yunis, KA, 2013) |
| "When asked to address the above question, findings that appeared to be among the most relevant included (1) interventions in the delivery room directed at supporting the physiological transition from intrauterine to extrauterine life rather than actively intervening in it; (2) recent data suggesting that keeping extremely low-gestational age neonates at a pulse oximeter saturation (SpO(2)) of 91-95% would increase their chances of survival compared with aiming for lower SpO(2) values; (3) using caffeine citrate in infants <1250 g with apnoea of prematurity improves neurodevelopmental outcome; (4) injecting antivascular epithelial growth factor into the vitreous seems to be an effective treatment for retinopathy of prematurity and (5) moderate hypothermia for perinatal hypoxic-ischaemic encephalopathy increases the likelihood of survival without neurological impairment." | 3.79 | What are the main research findings during the last 5 years that have changed my approach to clinical practice? ( Poets, CF, 2013) |
| "Three hundred and thirty-eight DBS cards for caffeine measurement were collected from 67 preterm infants (birth weight 0." | 3.79 | Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants. ( Della Pasqua, O; Field, DJ; Gade, S; Kairamkonda, V; Mulla, H; Pandya, HC; Patel, P; Spooner, N, 2013) |
| "Current knowledge suggests that laryngeal chemoreflexes (LCR) are involved in the occurrence of certain neonatal apneas/bradycardias, especially in the preterm newborn." | 3.79 | Effects of caffeine and/or nasal CPAP treatment on laryngeal chemoreflexes in preterm lambs. ( Bairam, A; Boudaa, N; Carrière, V; Germim, PS; Pasquier, JC; Praud, JP; Samson, N, 2013) |
| "We measured the duration of apnea induced by sustained end-inspiratory lung inflation (the Hering Breuer Reflex, HBR) in unanesthetized infant rat pups aged 4 days (P4) to P20 at body temperatures of 32°C and 36°C." | 3.79 | Influence of age, body temperature, GABAA receptor inhibition and caffeine on the Hering-Breuer inflation reflex in unanesthetized rat pups. ( Arnal, AV; Bartlett, D; Gore, JL; Leiter, JC; Rudkin, A, 2013) |
| "To determine the cost-effectiveness of treatment with caffeine compared with placebo for apnea of prematurity in infants with birth weights less than 1250 g, from birth through 18 to 21 months' corrected age." | 3.77 | Economic evaluation of caffeine for apnea of prematurity. ( Doyle, LW; Dukhovny, D; Kamholz, KL; Kok, JH; Lorch, SA; Mao, W; Roberts, RS; Schmidt, B; Wang, N; Zupancic, JA, 2011) |
| "The mechanisms underlying the therapeutic function of caffeine on apneas in preterm neonates are not well determined." | 3.76 | Caffeine reduces apnea frequency and enhances ventilatory long-term facilitation in rat pups raised in chronic intermittent hypoxia. ( Bairam, A; Joseph, V; Julien, CA, 2010) |
| "Caffeine is a common treatment for apnea of prematurity." | 3.75 | Enhancement of the breathing frequency response to hypoxia by neonatal caffeine treatment in adult male rats: the role of testosterone. ( Bairam, A; Joseph, V; Kinkead, R; Lajeunesse, Y; Montandon, G, 2009) |
| "Administration of caffeine citrate (caffeine) has been a central component of the treatment of apnea of prematurity." | 3.75 | Acute hemodynamic effects of caffeine administration in premature infants. ( Bin-Nun, A; Ionchev, A; Meadow, W; Soloveychik, V; Sriram, S, 2009) |
| "Caffeine therapy reduces apnea of prematurity, promotes successful extubation from invasive positive-pressure ventilation, and decreases the incidence of bronchopulmonary dysplasia." | 3.74 | Serum caffeine concentrations in preterm neonates. ( Hutchison, AA; Leon, AE; Ma, CX; Michienzi, K, 2007) |
| "Our goal was to determine the value of measuring plasma caffeine levels in preterm neonates treated with caffeine for apnea." | 3.74 | Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise? ( Aranda, JV; Botica, ML; Natarajan, G; Thomas, R, 2007) |
| "Caffeine is an adenosine receptor antagonist commonly used as a respiratory stimulant to treat neonatal apneas of premature newborn." | 3.73 | Long-term consequences of neonatal caffeine on ventilation, occurrence of apneas, and hypercapnic chemoreflex in male and female rats. ( Bairam, A; Kinkead, R; Montandon, G, 2006) |
| "We correlated plasma and urinary levels of caffeine in preterm infants treated with this drug for apnea of prematurity." | 3.73 | Correlation between plasma and urinary caffeine levels in preterm infants. ( Cattarossi, L; Logreco, P; Macagno, F; Savoia, M; Violino, M, 2006) |
| "Caffeine citrate is commonly used for prophylaxis and treatment of apnea in preterm babies." | 3.73 | [Caffeine citrate utilization for treatment of apnea in French neonatal units]. ( Baudon, JJ; Biran-Mucignat, V; Ducrocq, S; Gold, F; Lebas, F, 2006) |
| "Apnea of prematurity develop during the first days of life and usually resolve by the time the infant reaches 36-37 weeks postmenstrual age." | 3.73 | [Apnea of prematurity: risk factors and ambulatory treatment with caffeine citrate]. ( Baudon, JJ; Biran-Mucignat, V; Boelle, PY; Ducrocq, S; Gold, F; Lebas, F, 2006) |
| " This study evaluates the effect of caffeine on oxygen consumption and metabolic rate in premature infants with idiopathic apnea." | 3.71 | Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. ( Bauer, J; Hentschel, R; Linderkamp, O; Maier, K, 2001) |
| "To report the occurrence of apnea and bradycardia in two former pre-term infants who received spinal anaesthesia without inhalational or intravenous anaesthetic agents during inguinal herniorrhaphy." | 3.70 | Apnea following spinal anaesthesia in two former pre-term infants. ( Burd, RS; Helikson, MA; Tobias, JD, 1998) |
| "A retrospective review was done to identify infants who received caffeine therapy for RSV-associated apnea." | 3.70 | Caffeine in the treatment of apnea associated with respiratory syncytial virus infection in neonates and infants. ( Tobias, JD, 2000) |
| "To determine whether predischarge event recording (PDER) can accurately identify preterm infants with resolving apnea of prematurity (AOP) at risk for postdischarge complications." | 3.70 | Prediction of postdischarge complications by predischarge event recordings in infants with apnea of prematurity. ( DeCristofaro, JD; Katz, S; Subhani, M, 2000) |
| "Theophylline has been widely used to treat apnea of premature neonates." | 3.70 | Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea. ( Ahn, HW; Choi, JH; Park, KJ; Shin, WG; Suh, OK, 1999) |
| "Apnea of prematurity is a common problem in neonatal intensive care nurseries." | 3.68 | Plasma beta-endorphin concentration and xanthine treatment in apnea of prematurity. ( Hindmarsh, KW; Kalapurackal, M; Sankaran, K; Tan, L, 1993) |
| "The effectiveness of caffeine citrate in preventing idiopathic apnea in premature infants was evaluated." | 3.68 | Effectiveness and side effects of two different doses of caffeine in preventing apnea in premature infants. ( Carnevale, A; Chiarotti, M; De Carolis, MP; De Giovanni, N; Muzii, U; Romagnoli, C; Tortorolo, G; Zecca, E, 1992) |
| "The simultaneous determination of caffeine and theophylline plasmatic levels has been proposed when the later is used in the treatment of the newborn's apnea." | 3.68 | [Importance of monitoring theophylline and caffeine plasma levels in the management of neonatal apnea]. ( Sacristán del Castillo, JA; Soto Alvarez, J, 1991) |
| " The infant developed apnea, and not having known the above maternal history, was started on caffeine therapy." | 3.67 | Maternal coffee drinking and unusually high concentrations of caffeine in the newborn. ( Khanna, NN; Somani, SM, 1984) |
| "Caffeine, used for treatment of idiopathic apnea in preterm infants, may have a vasoconstrictive effect on cerebral vessels." | 3.67 | Does caffeine affect cerebral blood flow in the preterm infant? ( Baan, J; Ruys, JH; Stijnen, T; Van Bel, F; Van de Bor, M, 1989) |
| "Administering caffeine citrate is a safe, noninvasive way to treat premature infants with persistent apnea." | 3.67 | Caffeine citrate in the NICU. ( Flood, E, 1989) |
| " Comparison of the groups using quantitative measures of apnea, bradycardia, and periodic breathing obtained from pneumogram analysis and the incidence of monitor alarms on bedside nursing records showed no significant differences." | 3.67 | Transplacentally acquired caffeine and the occurrence of apnea, bradycardia, and periodic breathing in preterm infants: preliminary communication. ( Braun, RJ; Evans, MA; Kelly, DH; McCulloch, KM; Simms, PE, 1989) |
| "Four premature neonates and eight infants 1-19 months old received caffeine for apnea." | 3.67 | Maturation of caffeine N-demethylation in infancy: a study using the 13CO2 breath test. ( Badoual, J; Blais, JC; Carrier, O; d'Athis, P; Moran, C; Olive, G; Plissonnier, M; Pons, G; Rey, E; Richard, MO, 1988) |
| "Five neonates (4 premature) and 16 infants (6 prematurely born), 15-588 days old, received caffeine as citrate salt for apnea." | 3.67 | Developmental changes of caffeine elimination in infancy. ( Badoual, J; Carrier, O; d'Athis, P; Moran, C; Olive, G; Pons, G; Rey, E; Richard, MO, 1988) |
| "Theophylline and caffeine are two xanthine-derivated drugs frequently administered for their stimulating effects on the respiratory center in premature babies presenting with "idiopathic apnea"." | 3.67 | [Xanthines in apnea of premature infants. Influence on gastroesophageal reflux]. ( Sacré, L; Vandenplas, Y, 1987) |
| "This review provides an understanding of current problems related to apnea of infancy." | 3.67 | Infant apnea. ( Fox, WW; Spitzer, AR, 1986) |
| "To evaluate the relationship of antecedent maternal smoking and caffeine consumption habits on the occurrence of apnea in their offspring, rates for central and obstructive apnea were analyzed in a cohort of mother-infant pairs." | 3.67 | Effects of maternal smoking and caffeine habits on infantile apnea: a retrospective study. ( Bendell, D; Duke, JC; Mattice, CD; McCaffree, MA; Orr, WC; Toubas, PL, 1986) |
| "We report two infants with near miss sudden infant death syndrome events exhibiting seizure disorders after caffeine treatment, suggesting there is an infant subgroup diagnosed as near miss sudden infant death syndrome who have apnoea possibly with seizures whose seizure threshold may be lowered by central nervous system stimulants like caffeine." | 3.67 | Apnoea and seizures. ( Aranda, JV; Davis, JM; Metrakos, K, 1986) |
| " Because caffeine is a respiratory stimulant, its effect on breathing pattern was evaluated in 12 infants with infantile apnea." | 3.66 | Effect of caffeine on control of breathing in infantile apnea. ( Aranda, JV; Davis, J; Grondin, D; Trippenbach, T; Turmen, T; Watters, G; Zinman, R, 1983) |
| "The interactive effect of caffeine and continuous distending airway pressure was evaluated in two premature neonates with apnea." | 3.66 | Interaction of caffeine and continuous distending airway pressure in neonatal apnea. ( Aranda, JV; Outerbridge, EW; Trippenbach, T, 1983) |
| "We studied the effects of intravenous administration of 20 mg/kg caffeine citrate on glucose homeostasis, cardiorespiratory status, and urinary excretion of catecholamines and electrolytes in 12 premature infants with recurrent apnea." | 3.66 | The metabolic effects of caffeine in the newborn infant. ( Maisels, MJ; Marks, KH; Rothberg, AD; Ward, RM, 1981) |
| " Treatment of neonatal apnea with theophylline as documented by a normal follow-up pneumocardiogram should be considered successful only when the levels of both theophylline and caffeine have been documented subtherapeutic at time of re-test." | 3.66 | Effect of serum caffeine level on pneumocardiogram of premature infants treated for apnea with theophylline. ( Banagale, RC, 1982) |
| "Theophylline and caffeine are both effective stimulants of the central nervous system for the therapy of neonatal apnea." | 3.66 | Pharmacologic considerations in the therapy of neonatal apnea. ( Aranda, JV; Grondin, D; Sasyniuk, BI, 1981) |
| " This view assumes that pharmacologic manipulation of apnea of prematurity is in itself a desirable goal and clearly superior to treatment of apneic episodes when they occur." | 3.66 | Adverse effects of caffeine and theophylline in the newborn infant. ( Aranda, JV; Clozel, M; Howell, J, 1981) |
| "Simultaneous blood and saliva samples were drawn for determination of caffeine and theophylline concentrations in 17 infants receiving caffeine or theophylline therapy for apnea of prematurity." | 3.66 | Use of salivary concentrations in the prediction of serum caffeine and theophylline concentrations in premature infants. ( Bada, HS; Khanna, NN; Somani, SM, 1980) |
| "Growth, neurologic, and ophthalmologic assessments were done in 21 low-birth-weight infants given caffeine for neonatal apnea and in 21 matched control infants." | 3.66 | Sequelae of caffeine treatment in preterm infants with apnea. ( Aranda, JV; Gunn, TR; Metrakos, K; Riley, P; Willis, D, 1979) |
| "The pharmacokinetic profile of caffeine was studied in 32 premature newborn infants with apnea: 12 following a single intravenous dose; 3 after a single oral dose; 7 during treatment with an initial empirical (high) maintenance dose schedule; and 10 during treatment with a revised (lower) dose schedule." | 3.66 | Pharmacokinetic profile of caffeine in the premature newborn infant with apnea. ( Aldridge, A; Aranda, JV; Collinge, JM; Cook, CE; Gorman, W; Loughnan, PM; Neims, AH; Outerbridge, EW, 1979) |
| "Plasma concentrations of theophylline and caffeine in seven premature neonates receiving theophylline orally for treatment of apnea at age one to 9 days were measured by high performance liquid chromatography, ultraviolet spectrophotometry, and mass spectrometry." | 3.66 | Metabolism of theophylline to caffeine in premature newborn infants. ( Aranda, JV; Baltassat, P; Bethenod, M; Bory, C; Frederich, A; Porthault, M, 1979) |
| " Caffeine produced from theophylline may add to the pharmacologic effects of theophylline in newborn infants with apnea." | 3.66 | Metabolism of theophylline to caffeine in human fetal liver. ( Aldridge, A; Aranda, JV; Haber, R; Louridas, AT; Thom, P; Vitullo, BB, 1979) |
| "The efficacy of caffeine citrate in the management of apnea in the newborn infant was evaluated." | 3.65 | Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. ( Aranda, JV; Bergsteinsson, H; Gorman, W; Gunn, T, 1977) |
| "If caffeine was found to have a greater effect, this would influence prescribing habits." | 2.69 | Comparison of the effects of theophylline and caffeine on serum erythropoietin concentration in premature infants. ( Fang, S; Gamsu, HR; Greenough, A; Marsden, JT; Peters, TJ; Sherwood, RA, 1998) |
| "Caffeine as first-line treatment demonstrated similar efficacy to theophylline or aminophylline (theophylline ethylenediamine) in 4 small randomised studies." | 2.41 | Caffeine citrate: a review of its use in apnoea of prematurity. ( Comer, AM; Figgitt, DP; Perry, CM, 2001) |
| " Long term use produces tolerance to some of the pharmacological effects." | 2.39 | Pharmacological rationale for the clinical use of caffeine. ( Sawynok, J, 1995) |
| " Population pharmacokinetic modelling of caffeine in Chinese preterm newborn on a population-wide scale was conducted using NONMEM." | 1.62 | Developmental population pharmacokinetics of caffeine in Chinese premature infants with apnoea of prematurity: A post-marketing study to support paediatric labelling in China. ( Gao, XB; Jacqz-Aigrain, E; Jiang, ZH; Ni, SQ; Wang, CH; Wu, YE; Yang, F; Zhao, W; Zheng, Y, 2021) |
| "Caffeine treatment is a preferred treatment choice." | 1.62 | Therapy for Apnoea of Prematurity: A Retrospective Study on Effects of Standard Dose and Genetic Variability on Clinical Response to Caffeine Citrate in Chinese Preterm Infants. ( Chen, F; Cheng, R; Guo, HL; He, X; Jia, WW; Li, L; Liu, Y; Lu, KY; Ni, MM; Qiu, JC; Xu, J, 2021) |
| "Caffeine citrate was used in extremely premature infants at younger gestation, at higher doses, and for longer durations than recommended on the drug label." | 1.51 | Dosing and Safety of Off-label Use of Caffeine Citrate in Premature Infants. ( Bendel-Stenzel, E; Chhabra, R; Harper, B; Ku, L; Laughon, M; Moya, F; Payne, EH; Puia-Dumitrescu, M; Smith, PB; Soriano, A; Wade, KC; Zhao, J, 2019) |
| "To identify dosing strategies that will assure stable caffeine concentrations in preterm neonates despite changing caffeine clearance during the first 8 weeks of life." | 1.46 | Caffeine Citrate Dosing Adjustments to Assure Stable Caffeine Concentrations in Preterm Neonates. ( Datta, AN; Jost, K; Koch, G; Pfister, M; Schulzke, SM; van den Anker, J, 2017) |
| "The dosing regimen studied was suitable for our local Asian neonates as it resulted in therapeutic caffeine concentrations for adequate treatment of apnoea." | 1.31 | Caffeine in apnoeic Asian neonates: a sparse data analysis. ( Chirino-Barcelo, Y; Khoo, YM; Lee, HS; Ong, D; Tan, KL, 2002) |
| "Caffeine clearance has traditionally been reported as either an absolute value or as directly proportional to body weight." | 1.30 | Caffeine overdose in a premature infant: clinical course and pharmacokinetics. ( Anderson, BJ; Gunn, TR; Holford, NH; Johnson, R, 1999) |
| "Caffeine led to an increase in the mean arterial blood pressure on the first 3 days of therapy, but the heart rate did not change." | 1.28 | Cardiovascular effects of caffeine therapy in preterm infants. ( Erickson, R; Sims, ME; Walther, FJ, 1990) |
| "Caffeine was administered for 3." | 1.27 | Effect of caffeine on pneumogram and apnoea of infancy. ( Anwar, M; Graff, M; Hegyi, T; Hiatt, M; Mojica, N; Mondestin, H; Novo, R, 1986) |
| " Qualitative and quantitative differences in pharmacokinetics and pharmacodynamics of drugs should be considered before dosage regimens can be established." | 1.27 | [Peculiarities of drug therapy in childhood]. ( Kusenbach, G; Reinhardt, D, 1986) |
| " The elevated blood caffeine levels in breast-fed infants was not related to higher daily dosage of caffeine citrate (4." | 1.27 | Delay in caffeine elimination in breast-fed infants. ( Billon, B; Le Guennec, JC, 1987) |
| "Caffeine half-life was greatly increased in two infants who had cholestatic hepatitis secondary to prolonged parenteral alimentation and one infant who was breast-fed exclusively." | 1.27 | Maturational changes of caffeine concentrations and disposition in infancy during maintenance therapy for apnea of prematurity: influence of gestational age, hepatic disease, and breast-feeding. ( Billon, B; Le Guennec, JC; Paré, C, 1985) |
| " The mean plasma half-live of theophylline was 22." | 1.26 | [Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)]. ( Lipowsky, G; Riechert, M; Stiegler, H; Stöckl, H, 1981) |
| "Caffeine was detectable in plasma at birth, and in preterm infants not receiving theophylline; plasma levels of caffeine tended to be similar to the levels in their mothers' milk." | 1.26 | Plasma xanthine levels in low birthweight infants treated or not treated with theophylline. ( Brazier, JL; Renaud, H; Ribon, B; Salle, BL, 1979) |
Research
Studies (302)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 73 (24.17) | 18.7374 |
| 1990's | 28 (9.27) | 18.2507 |
| 2000's | 41 (13.58) | 29.6817 |
| 2010's | 104 (34.44) | 24.3611 |
| 2020's | 56 (18.54) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Saini, SS | 1 |
| Kumar, P | 1 |
| Seppä-Moilanen, M | 2 |
| Andersson, S | 2 |
| Kirjavainen, T | 2 |
| Ariagno, S | 1 |
| Thorvilson, M | 1 |
| Andersen, L | 1 |
| Collura, C | 1 |
| Yuan, Y | 1 |
| Yang, Y | 1 |
| Lei, X | 1 |
| Dong, W | 1 |
| Iranpour, R | 2 |
| Armanian, AM | 2 |
| Miladi, N | 1 |
| Feizi, A | 1 |
| Chavez, L | 1 |
| Bancalari, E | 3 |
| Shi, H | 1 |
| Tu, Y | 1 |
| Li, Y | 3 |
| Ma, C | 1 |
| Gyabaah, AT | 1 |
| Yu, C | 1 |
| Li, Z | 3 |
| Chen, J | 2 |
| Huang, ZL | 1 |
| Cai, X | 1 |
| Smith, A | 1 |
| Egan, R | 1 |
| Boyle, MA | 1 |
| McElligott, F | 1 |
| Long, JY | 1 |
| Hu, YH | 2 |
| Xia, Y | 1 |
| Du, FF | 1 |
| Dai, HR | 2 |
| Tian, M | 1 |
| Xu, J | 3 |
| Cheng, R | 4 |
| Ding, XS | 2 |
| Guo, HL | 3 |
| Chen, F | 3 |
| Xie, JB | 1 |
| Lin, XZ | 1 |
| Yun, WZ | 1 |
| Kassab, YW | 1 |
| Yao, LM | 1 |
| Khairuddin, N | 1 |
| Ming, LC | 1 |
| Hadi, MA | 1 |
| Liu, Y | 3 |
| Lu, KY | 2 |
| He, X | 2 |
| Jiao, Z | 1 |
| Miao, Y | 2 |
| Zhou, Y | 1 |
| Zhao, S | 2 |
| Liu, W | 2 |
| Wang, A | 2 |
| Zhang, Y | 4 |
| Jiang, H | 2 |
| García-Robles, A | 1 |
| Solaz-García, Á | 1 |
| Verdú-Andrés, J | 1 |
| Andrés, JLP | 1 |
| Cañada-Martínez, AJ | 1 |
| Pericás, CC | 1 |
| Ponce-Rodriguez, HD | 1 |
| Vento, M | 1 |
| González, PS | 1 |
| Dani, C | 3 |
| Cecchi, A | 1 |
| Ciarcià, M | 2 |
| Miselli, F | 1 |
| Luzzati, M | 1 |
| Remaschi, G | 1 |
| Bona, MD | 1 |
| la Marca, G | 1 |
| Boni, L | 1 |
| Ambreen, G | 1 |
| Kumar, M | 2 |
| Ali, A | 1 |
| Shah, SAA | 1 |
| Saleem, SM | 1 |
| Tahir, A | 1 |
| Salat, MS | 1 |
| Aslam, MS | 1 |
| Hussain, K | 1 |
| Prakash, R | 2 |
| Kannan Loganathan, P | 1 |
| Nair, V | 1 |
| Bruschettini, M | 9 |
| Brattström, P | 3 |
| Russo, C | 3 |
| Onland, W | 4 |
| Davis, PG | 9 |
| Soll, R | 4 |
| Fusco, M | 1 |
| Manti, S | 1 |
| Marseglia, L | 1 |
| Leonardi, V | 1 |
| Corsini, I | 1 |
| Gitto, E | 1 |
| Schmidt, B | 12 |
| Teng, P | 1 |
| Sugino, M | 1 |
| Kuboi, T | 1 |
| Noguchi, Y | 1 |
| Nishioka, K | 1 |
| Tadatomo, Y | 1 |
| Kawaguchi, N | 1 |
| Sadamura, T | 1 |
| Nakano, A | 1 |
| Konishi, Y | 1 |
| Koyano, K | 1 |
| Nakamura, S | 1 |
| Okada, H | 1 |
| Itoh, S | 1 |
| Kusaka, T | 1 |
| Atalah, YEY | 1 |
| Barış, HE | 1 |
| Akdere, SK | 1 |
| Sabancı, M | 1 |
| Özdemir, H | 1 |
| Gücüyener, K | 1 |
| Eralp, EE | 1 |
| Özek, E | 1 |
| Boran, P | 1 |
| Moresco, L | 1 |
| Sjögren, A | 1 |
| Marques, KA | 2 |
| Evans, S | 1 |
| Avdic, E | 1 |
| Pessano, S | 1 |
| Fiander, M | 2 |
| Roehr, CC | 1 |
| Maeda, T | 1 |
| Sekiguchi, K | 1 |
| Wasada, R | 1 |
| Ihara, K | 1 |
| Mitchell, L | 1 |
| MacFarlane, PM | 1 |
| Rostas, SE | 1 |
| McPherson, C | 1 |
| Johansson, M | 2 |
| Juhl Jørgensen, K | 1 |
| Ji, D | 1 |
| Smith, PB | 2 |
| Clark, RH | 1 |
| Zimmerman, KO | 1 |
| Laughon, M | 2 |
| Ku, L | 2 |
| Greenberg, RG | 1 |
| Heuzé, N | 1 |
| Goyer, I | 1 |
| Porcheret, F | 1 |
| Denis, M | 1 |
| Faucon, C | 1 |
| Jokic, M | 1 |
| Brossier, D | 1 |
| Nylander Vujovic, S | 1 |
| Nava, C | 1 |
| Chung, J | 1 |
| Tran Lopez, K | 1 |
| Amendolia, B | 1 |
| Bhat, V | 1 |
| Nakhla, T | 1 |
| Slater-Myer, L | 1 |
| Saslow, J | 1 |
| Aghai, ZH | 1 |
| Alhersh, E | 1 |
| Abushanab, D | 1 |
| Al-Shaibi, S | 1 |
| Al-Badriyeh, D | 1 |
| Wan, L | 1 |
| Huang, L | 2 |
| Chen, P | 1 |
| He, T | 1 |
| Liao, ZC | 1 |
| Ding, Y | 1 |
| Wang, MJ | 1 |
| Li, W | 1 |
| Gan, JM | 1 |
| Yue, SJ | 1 |
| Liu, S | 1 |
| Zhang, X | 4 |
| Yuan, X | 1 |
| Yang, L | 1 |
| Zhang, R | 1 |
| Wang, X | 1 |
| Xu, F | 1 |
| Zhu, C | 1 |
| Gao, XB | 1 |
| Zheng, Y | 1 |
| Yang, F | 1 |
| Wang, CH | 1 |
| Jiang, ZH | 1 |
| Wu, YE | 1 |
| Jacqz-Aigrain, E | 1 |
| Ni, SQ | 1 |
| Zhao, W | 1 |
| Guo, A | 1 |
| Zhu, Z | 1 |
| Xue, J | 1 |
| Di, X | 1 |
| Fan, J | 1 |
| Zhao, P | 1 |
| Hu, X | 1 |
| Xie, H | 1 |
| Oliphant, EA | 1 |
| McKinlay, CJD | 1 |
| McNamara, DG | 2 |
| Alsweiler, JM | 1 |
| Synnes, A | 1 |
| Grunau, RE | 6 |
| Cheong, JLY | 2 |
| Doyle, LW | 14 |
| Saroha, V | 2 |
| Patel, RM | 3 |
| Qiu, JC | 1 |
| Li, L | 1 |
| Jia, WW | 1 |
| Ni, MM | 1 |
| Eichenwald, EC | 1 |
| Ekhaguere, OA | 1 |
| Ayede, AI | 1 |
| Ezeaka, CV | 1 |
| Aranda, JV | 18 |
| Beharry, KD | 1 |
| Pournami, F | 1 |
| Prabhakar, J | 1 |
| Nandakumar, A | 1 |
| Nair, PMC | 1 |
| Jain, N | 1 |
| Engbers, AGJ | 1 |
| Völler, S | 1 |
| Poets, CF | 7 |
| Knibbe, CAJ | 1 |
| Reiss, IKM | 1 |
| Koch, BCP | 1 |
| Flint, RB | 1 |
| Simons, SHP | 1 |
| Conlon, S | 1 |
| Di Fiore, JM | 2 |
| Martin, RJ | 4 |
| Elmowafi, M | 1 |
| Mohsen, N | 1 |
| Nour, I | 2 |
| Nasef, N | 2 |
| Mohd Kori, AM | 1 |
| Van Rostenberghe, H | 1 |
| Ibrahim, NR | 1 |
| Yaacob, NM | 1 |
| Nasir, A | 1 |
| Jiang, Z | 1 |
| Gao, X | 1 |
| Liang, J | 1 |
| Ni, S | 1 |
| Rosen, C | 1 |
| Taran, C | 1 |
| Hanna, M | 1 |
| Gueta, I | 1 |
| Loebstein, R | 1 |
| Strauss, T | 1 |
| Yarden-Bilavsky, H | 1 |
| Roberts, RS | 10 |
| Anderson, PJ | 5 |
| Asztalos, EV | 4 |
| Costantini, L | 3 |
| Dewey, D | 3 |
| D'Ilario, J | 3 |
| Moddemann, D | 5 |
| Nelson, H | 2 |
| Ohlsson, A | 5 |
| Solimano, A | 5 |
| Tin, W | 6 |
| Shivakumar, M | 3 |
| Jayashree, P | 2 |
| Najih, M | 1 |
| Lewis, LES | 3 |
| Bhat Y, R | 1 |
| Kamath, A | 2 |
| Shashikala, - | 1 |
| Ranganathan, S | 1 |
| Abu-Shaweesh, JM | 1 |
| Koch, G | 1 |
| Datta, AN | 1 |
| Jost, K | 1 |
| Schulzke, SM | 1 |
| van den Anker, J | 1 |
| Pfister, M | 1 |
| O'Halloran, KD | 2 |
| McDonald, FB | 2 |
| Khurana, S | 1 |
| Sujith Kumar Reddy, GV | 1 |
| Ramesh Bhat, Y | 1 |
| Chalwadi, UK | 1 |
| Kalappanavar, NK | 1 |
| Simon Lewis, LE | 1 |
| Gentle, SJ | 1 |
| Travers, CP | 1 |
| Carlo, WA | 1 |
| Nagasato, A | 1 |
| Nakamura, M | 1 |
| Kamimura, H | 1 |
| Vliegenthart, R | 1 |
| Miedema, M | 2 |
| Hutten, GJ | 2 |
| van Kaam, AH | 3 |
| Dix, LML | 1 |
| van Bel, F | 2 |
| Baerts, W | 1 |
| Lemmers, PMA | 1 |
| Mürner-Lavanchy, IM | 1 |
| Dobson, NR | 2 |
| Hunt, CE | 1 |
| Dempsey, EM | 1 |
| M, S | 1 |
| Nayak, K | 1 |
| Purkayastha, J | 1 |
| Rantakari, K | 1 |
| Mikkola, K | 1 |
| Ley, D | 2 |
| Huvanandana, J | 1 |
| Thamrin, C | 1 |
| Hinder, M | 1 |
| McEwan, A | 1 |
| Tracy, MB | 1 |
| Álvarado Socarras, JL | 1 |
| Dong, LB | 1 |
| Li, YF | 1 |
| Qiao, S | 1 |
| Feng, Y | 1 |
| Zhao, L | 1 |
| Chen, X | 2 |
| Mao, XN | 1 |
| Qiu, J | 1 |
| Vliegenthart, RJS | 1 |
| Jin, L | 1 |
| Jain, VG | 1 |
| Jobe, A | 1 |
| Kou, C | 1 |
| Han, D | 1 |
| Wu, W | 1 |
| Liu, Z | 1 |
| Gao, Z | 1 |
| Puia-Dumitrescu, M | 1 |
| Zhao, J | 1 |
| Soriano, A | 1 |
| Payne, EH | 1 |
| Harper, B | 1 |
| Bendel-Stenzel, E | 1 |
| Moya, F | 1 |
| Chhabra, R | 1 |
| Wade, KC | 1 |
| Zhang, HT | 1 |
| Lyu, Y | 1 |
| Wang, LF | 1 |
| Yang, ZY | 1 |
| Chawla, R | 1 |
| Haloi, P | 1 |
| Singh, M | 1 |
| Abu Jawdeh, EG | 1 |
| O'Riordan, M | 1 |
| Limrungsikul, A | 1 |
| Bandyopadhyay, A | 1 |
| Argus, BM | 1 |
| Nakad, PE | 1 |
| Supapannachart, S | 1 |
| Yunis, KA | 1 |
| Vatlach, S | 1 |
| Arand, J | 1 |
| Engel, C | 1 |
| Schoen, K | 1 |
| Yu, T | 2 |
| Stockmann, C | 1 |
| Spigarelli, MG | 1 |
| Sherwin, CM | 2 |
| Ulanovsky, I | 1 |
| Haleluya, NS | 1 |
| Blazer, S | 1 |
| Weissman, A | 1 |
| O'Brien, K | 1 |
| Sankaran, K | 2 |
| Herlenius, E | 1 |
| Roberts, R | 1 |
| Kreutzer, K | 1 |
| Bassler, D | 1 |
| Maitre, NL | 2 |
| Chan, J | 1 |
| Stark, AR | 2 |
| Lambert, WE | 1 |
| Aschner, JL | 1 |
| Key, AP | 1 |
| Butler, TJ | 1 |
| Firestone, KS | 1 |
| Grow, JL | 1 |
| Kantak, AD | 1 |
| Marcus, CL | 2 |
| Meltzer, LJ | 1 |
| Traylor, J | 1 |
| Dix, J | 1 |
| Asztalos, E | 2 |
| Opie, G | 1 |
| Biggs, SN | 1 |
| Nixon, GM | 2 |
| Narang, I | 1 |
| Bhattacharjee, R | 1 |
| Davey, M | 1 |
| Horne, RS | 1 |
| Cheshire, M | 1 |
| Gibbons, J | 1 |
| Bradford, R | 1 |
| Khan, SR | 1 |
| Hassanein, SM | 1 |
| Gad, GI | 1 |
| Ismail, RI | 1 |
| Diab, M | 1 |
| Lodha, A | 1 |
| Seshia, M | 1 |
| McMillan, DD | 1 |
| Barrington, K | 1 |
| Yang, J | 1 |
| Lee, SK | 1 |
| Shah, PS | 1 |
| Xu, JL | 1 |
| Wang, RQ | 1 |
| Chen, DM | 1 |
| Araujo, P | 1 |
| Tufik, S | 1 |
| Andersen, ML | 1 |
| Mohr, MA | 1 |
| Vergales, BD | 1 |
| Lee, H | 1 |
| Clark, MT | 1 |
| Lake, DE | 1 |
| Mennen, AC | 1 |
| Kattwinkel, J | 2 |
| Sinkin, RA | 1 |
| Moorman, JR | 2 |
| Fairchild, KD | 1 |
| Delos, JB | 1 |
| Ren, J | 1 |
| Ding, X | 1 |
| Greer, JJ | 1 |
| Mohammed, S | 1 |
| Shabaan, AE | 1 |
| Shouman, B | 1 |
| Abdel-Hady, H | 1 |
| Razak, A | 1 |
| Nagesh, NK | 1 |
| Parikka, V | 1 |
| Beck, J | 1 |
| Zhai, Q | 1 |
| Leppäsalo, J | 1 |
| Lehtonen, L | 1 |
| Soukka, H | 1 |
| Bairam, A | 9 |
| Uppari, N | 1 |
| Mubayed, S | 1 |
| Joseph, V | 5 |
| Doyle, J | 1 |
| Davidson, D | 1 |
| Katz, S | 2 |
| Varela, M | 1 |
| Demeglio, D | 1 |
| DeCristofaro, J | 1 |
| Gauda, E | 1 |
| MacFarlane, P | 1 |
| Park, HW | 1 |
| Lim, G | 1 |
| Chung, SH | 1 |
| Chung, S | 1 |
| Kim, KS | 1 |
| Kim, SN | 1 |
| Zhao, Y | 1 |
| Tian, X | 1 |
| Liu, G | 1 |
| Lista, G | 1 |
| Fabbri, L | 1 |
| Polackova, R | 1 |
| Kiechl-Kohlendorfer, U | 1 |
| Papagaroufalis, K | 1 |
| Saenz, P | 1 |
| Ferrari, F | 1 |
| Lasagna, G | 1 |
| Carnielli, VP | 1 |
| Carlos, C | 1 |
| Hageman, J | 1 |
| Pellerite, M | 1 |
| McEntire, B | 1 |
| Cóté, A | 1 |
| Raoux, A | 1 |
| Franco, P | 1 |
| Rusciolelli, C | 1 |
| Consenstein, L | 1 |
| Kelly, D | 1 |
| Oñatibia-Astibia, A | 1 |
| Martínez-Pinilla, E | 1 |
| Franco, R | 1 |
| Fairchild, K | 1 |
| Mohr, M | 1 |
| Paget-Brown, A | 1 |
| Tabacaru, C | 1 |
| Lake, D | 1 |
| Delos, J | 1 |
| Yu, M | 1 |
| Huang, JH | 1 |
| Zhu, R | 1 |
| Zhang, XZ | 1 |
| Wu, WY | 1 |
| Wen, XH | 1 |
| Faghihian, E | 1 |
| Salehimehr, N | 1 |
| Chavez-Valdez, R | 1 |
| Ahlawat, R | 1 |
| Wills-Karp, M | 1 |
| Gauda, EB | 1 |
| Alansari, K | 1 |
| Toaimah, FH | 1 |
| Khalafalla, H | 1 |
| El Tatawy, LA | 1 |
| Davidson, BL | 1 |
| Ahmed, W | 1 |
| Balch, AH | 1 |
| Ward, RM | 2 |
| Korgenski, EK | 1 |
| Barco, S | 1 |
| Romantsik, O | 1 |
| Risso, F | 1 |
| Gennai, I | 1 |
| Chinea, B | 1 |
| Ramenghi, LA | 1 |
| Tripodi, G | 1 |
| Cangemi, G | 1 |
| Chen, C | 1 |
| Shu, XX | 1 |
| Yang, XY | 1 |
| Shi, J | 1 |
| Tang, J | 1 |
| Mu, DZ | 1 |
| Powell, MB | 1 |
| Ahlers-Schmidt, CR | 1 |
| Engel, M | 1 |
| Bloom, BT | 1 |
| Vliegenthart, RJ | 1 |
| Ten Hove, CH | 1 |
| Maheux, A | 1 |
| Pladys, P | 1 |
| Laviolle, B | 1 |
| Atik, A | 1 |
| Harding, R | 1 |
| De Matteo, R | 1 |
| Kondos-Devcic, D | 1 |
| Cheong, J | 1 |
| Tolcos, M | 1 |
| Wei, QZ | 1 |
| Su, P | 1 |
| Han, JT | 1 |
| Duan, YH | 1 |
| Gray, PH | 2 |
| Chauhan, M | 1 |
| Montenegro, BL | 1 |
| Amberson, M | 1 |
| Veit, L | 1 |
| Freiberger, C | 1 |
| Dukhovny, D | 2 |
| Rhein, LM | 1 |
| Ahmad, A | 1 |
| Mondal, T | 1 |
| Klein, B | 1 |
| Sun, JJ | 1 |
| Nanu, R | 1 |
| Ray, RS | 1 |
| Uppari, NP | 1 |
| Montandon, G | 2 |
| Lajeunesse, Y | 1 |
| Kinkead, R | 2 |
| Soloveychik, V | 1 |
| Bin-Nun, A | 1 |
| Ionchev, A | 1 |
| Sriram, S | 1 |
| Meadow, W | 1 |
| Charles, BG | 2 |
| Townsend, SR | 1 |
| Steer, PA | 4 |
| Flenady, VJ | 2 |
| Shearman, A | 2 |
| Verder, H | 1 |
| Bohlin, K | 1 |
| Kamper, J | 1 |
| Lindwall, R | 1 |
| Jonsson, B | 1 |
| Skouroliakou, M | 1 |
| Bacopoulou, F | 1 |
| Markantonis, SL | 1 |
| Haslam, R | 1 |
| Sinha, S | 1 |
| Moriette, G | 4 |
| Lescure, S | 1 |
| El Ayoubi, M | 1 |
| Lopez, E | 1 |
| Henderson-Smart, DJ | 8 |
| Julien, CA | 2 |
| Winckworth, LC | 1 |
| Powell, E | 1 |
| Beharry, K | 2 |
| Valencia, GB | 1 |
| Natarajan, G | 2 |
| Davis, J | 3 |
| Mathew, OP | 1 |
| Rockley, TJ | 1 |
| De Paoli, AG | 2 |
| Lorch, SA | 1 |
| Kok, JH | 1 |
| Kamholz, KL | 1 |
| Wang, N | 1 |
| Mao, W | 1 |
| Zupancic, JA | 1 |
| Davis, P | 3 |
| Barrington, KJ | 3 |
| Vavasseur, C | 1 |
| Cesar, K | 1 |
| Iolster, T | 1 |
| White, D | 1 |
| Latifi, S | 1 |
| Patel, P | 1 |
| Mulla, H | 1 |
| Kairamkonda, V | 1 |
| Spooner, N | 1 |
| Gade, S | 1 |
| Della Pasqua, O | 1 |
| Field, DJ | 1 |
| Pandya, HC | 1 |
| Picone, S | 1 |
| Bedetta, M | 1 |
| Paolillo, P | 1 |
| Boudaa, N | 1 |
| Samson, N | 1 |
| Carrière, V | 1 |
| Germim, PS | 1 |
| Pasquier, JC | 1 |
| Praud, JP | 1 |
| Arnal, AV | 1 |
| Gore, JL | 1 |
| Rudkin, A | 1 |
| Bartlett, D | 1 |
| Leiter, JC | 1 |
| Bhatt-Mehta, V | 1 |
| Schumacher, RE | 1 |
| Cherif, A | 2 |
| Marrakchi, Z | 1 |
| Klouz, A | 2 |
| Chaouachi, S | 1 |
| Belkahia, C | 2 |
| Boukef-Larguèche, S | 2 |
| Zouari, B | 1 |
| GESHELIN, SA | 2 |
| Anderson, BJ | 2 |
| Marlier, L | 1 |
| Gaugler, C | 1 |
| Messer, J | 1 |
| Sajit, NT | 1 |
| Steggall, M | 1 |
| Padmakumar, B | 1 |
| Hoecker, C | 1 |
| Nelle, M | 1 |
| Beedgen, B | 1 |
| Rengelshausen, J | 1 |
| Linderkamp, O | 2 |
| Cattarossi, L | 2 |
| Violino, M | 1 |
| Macagno, F | 2 |
| Logreco, P | 2 |
| Savoia, M | 1 |
| Ducrocq, S | 2 |
| Biran-Mucignat, V | 2 |
| Lebas, F | 2 |
| Baudon, JJ | 2 |
| Gold, F | 2 |
| Boelle, PY | 1 |
| Coulter, DM | 1 |
| Hand, IL | 1 |
| Noble, LM | 1 |
| McCallum, AD | 1 |
| Duke, T | 1 |
| Leon, AE | 1 |
| Michienzi, K | 1 |
| Ma, CX | 1 |
| Hutchison, AA | 1 |
| Botica, ML | 1 |
| Thomas, R | 1 |
| Stevenson, DK | 1 |
| Haley, TJ | 1 |
| Labow, R | 1 |
| Dandurand, KR | 1 |
| Scalais, E | 1 |
| Papageorgiou, A | 1 |
| Khanna, NN | 6 |
| Somani, SM | 7 |
| Turmen, T | 4 |
| Trippenbach, T | 2 |
| Grondin, D | 2 |
| Zinman, R | 1 |
| Watters, G | 1 |
| Sourgens, H | 1 |
| Staib, AH | 1 |
| Bielicki, M | 1 |
| von Loewenich, V | 1 |
| Outerbridge, EW | 2 |
| Mullner, JW | 1 |
| Rothberg, AD | 1 |
| Marks, KH | 1 |
| Maisels, MJ | 1 |
| Lönnerholm, G | 2 |
| Lindström, B | 2 |
| Paalzow, L | 1 |
| Sedin, G | 1 |
| Hargreaves, DB | 1 |
| Lealman, GT | 1 |
| Mulley, BA | 1 |
| Horowitz, DA | 1 |
| Jablonski, WJ | 1 |
| Mehta, KA | 1 |
| Gorodischer, R | 1 |
| Karplus, M | 1 |
| Boyer, A | 1 |
| Miller, J | 1 |
| Chua, C | 1 |
| Menke, JA | 1 |
| Berthou, F | 1 |
| Alix, D | 1 |
| Riche, C | 1 |
| Picart, D | 1 |
| Dreano, Y | 1 |
| Gouedard, H | 1 |
| Banagale, RC | 1 |
| Bada, HS | 3 |
| Sasyniuk, BI | 1 |
| Howell, J | 1 |
| Clozel, M | 1 |
| Murat, I | 2 |
| Blin, MC | 1 |
| Couchard, M | 1 |
| Flouvat, B | 2 |
| De Gamarra, E | 2 |
| Relier, JP | 2 |
| Dreyfus-Brisac, C | 1 |
| Riechert, M | 2 |
| Lipowsky, G | 1 |
| Stöckl, H | 1 |
| Stiegler, H | 1 |
| Floberg, S | 1 |
| Sawynok, J | 1 |
| Lundstrøm, KE | 1 |
| Larsen, PB | 2 |
| Brendstrup, L | 2 |
| Skov, L | 2 |
| Greisen, G | 1 |
| Flachs, H | 1 |
| Welborn, LG | 3 |
| Greenspun, JC | 1 |
| Hindmarsh, KW | 1 |
| Tan, L | 1 |
| Kalapurackal, M | 1 |
| Sidhu, J | 1 |
| Triggs, E | 1 |
| Charles, B | 2 |
| Tudehope, D | 1 |
| Gray, P | 1 |
| Cowley, D | 1 |
| Duc, G | 1 |
| Bucher, HU | 1 |
| Calhoun, LK | 1 |
| Lee, TC | 2 |
| Steer, P | 5 |
| Flenady, V | 1 |
| Pesce, AJ | 1 |
| Rashkin, M | 1 |
| Kotagal, U | 1 |
| Fang, S | 1 |
| Sherwood, RA | 1 |
| Gamsu, HR | 1 |
| Marsden, JT | 1 |
| Peters, TJ | 1 |
| Greenough, A | 1 |
| Tobias, JD | 2 |
| Burd, RS | 1 |
| Helikson, MA | 1 |
| Huon, C | 1 |
| Rey, E | 4 |
| Mussat, P | 1 |
| Parat, S | 1 |
| du Preez, MJ | 1 |
| Botha, JH | 1 |
| McFadyen, ML | 1 |
| Adhikari, M | 1 |
| Gunn, TR | 2 |
| Holford, NH | 1 |
| Johnson, R | 1 |
| Darraj, S | 1 |
| Bohnhorst, B | 1 |
| Subhani, M | 1 |
| DeCristofaro, JD | 1 |
| Ahn, HW | 1 |
| Shin, WG | 1 |
| Park, KJ | 1 |
| Suh, OK | 1 |
| Choi, JH | 1 |
| Erenberg, A | 1 |
| Leff, RD | 1 |
| Haack, DG | 1 |
| Mosdell, KW | 1 |
| Hicks, GM | 1 |
| Wynne, BA | 1 |
| Bertini, G | 1 |
| Reali, MF | 1 |
| Tronchin, M | 1 |
| Wiechmann, L | 1 |
| Martelli, E | 1 |
| Rubaltelli, FF | 1 |
| Bhatia, J | 1 |
| Comer, AM | 1 |
| Perry, CM | 1 |
| Figgitt, DP | 1 |
| Bauer, J | 1 |
| Maier, K | 1 |
| Hentschel, R | 1 |
| Aggarwal, R | 1 |
| Singhal, A | 1 |
| Deorari, AK | 1 |
| Paul, VK | 1 |
| Choi, DM | 1 |
| Davis, L | 1 |
| Gannon, BA | 1 |
| Lee, HS | 1 |
| Khoo, YM | 1 |
| Chirino-Barcelo, Y | 1 |
| Tan, KL | 1 |
| Ong, D | 1 |
| Gorman, W | 2 |
| Bergsteinsson, H | 1 |
| Gunn, T | 1 |
| Bory, C | 2 |
| Baltassat, P | 2 |
| Porthault, M | 2 |
| Bethenod, M | 2 |
| Frederich, A | 2 |
| Boutroy, MJ | 3 |
| Vert, P | 4 |
| Monin, P | 2 |
| Royer, RJ | 2 |
| Royer-Morrot, MJ | 2 |
| Metrakos, K | 2 |
| Riley, P | 1 |
| Willis, D | 1 |
| Cook, CE | 1 |
| Collinge, JM | 1 |
| Loughnan, PM | 1 |
| Aldridge, A | 2 |
| Neims, AH | 1 |
| Brazier, JL | 1 |
| Renaud, H | 1 |
| Ribon, B | 1 |
| Salle, BL | 1 |
| Tin, AA | 1 |
| Louridas, TA | 1 |
| Louridas, AT | 1 |
| Vitullo, BB | 1 |
| Thom, P | 1 |
| Haber, R | 1 |
| Koppe, JG | 2 |
| de Bruijne, JI | 1 |
| de Boer, P | 1 |
| Lucey, JF | 1 |
| Martinet, Y | 1 |
| Debry, G | 1 |
| Romagnoli, C | 1 |
| De Carolis, MP | 1 |
| Muzii, U | 1 |
| Zecca, E | 1 |
| Tortorolo, G | 1 |
| Chiarotti, M | 1 |
| De Giovanni, N | 1 |
| Carnevale, A | 1 |
| Scanlon, JE | 1 |
| Chin, KC | 1 |
| Morgan, ME | 1 |
| Durbin, GM | 1 |
| Hale, KA | 1 |
| Brown, SS | 1 |
| van den Anker, JN | 1 |
| Jongejan, HT | 1 |
| Sauer, PJ | 1 |
| Merchant, RH | 1 |
| Irani, AJ | 1 |
| Amato, M | 1 |
| Isenschmid, M | 1 |
| Hüppi, P | 1 |
| Soto Alvarez, J | 1 |
| Sacristán del Castillo, JA | 1 |
| Aujard, Y | 1 |
| Morisot, C | 1 |
| Simoens, C | 1 |
| Trublin, F | 1 |
| Lhermitte, M | 2 |
| Gremillet, C | 1 |
| Robert, MH | 1 |
| Lequien, P | 2 |
| Walther, FJ | 1 |
| Erickson, R | 1 |
| Sims, ME | 1 |
| Van de Bor, M | 1 |
| Stijnen, T | 1 |
| Baan, J | 1 |
| Ruys, JH | 1 |
| Hannallah, RS | 2 |
| Fink, R | 2 |
| Ruttimann, UE | 2 |
| Hicks, JM | 1 |
| Fuglsang, G | 1 |
| Nielsen, K | 1 |
| Kjaer Nielsen, L | 1 |
| Sennels, F | 1 |
| Jakobsen, P | 1 |
| Thelle, T | 1 |
| Flood, E | 1 |
| Noerr, B | 1 |
| McCulloch, KM | 1 |
| Braun, RJ | 1 |
| Simms, PE | 1 |
| Evans, MA | 1 |
| Kelly, DH | 1 |
| Colacino, V | 1 |
| Janes, A | 1 |
| Rubini, S | 1 |
| Zilli, M | 1 |
| Gupta, P | 1 |
| Pons, G | 3 |
| Blais, JC | 1 |
| Plissonnier, M | 1 |
| Richard, MO | 3 |
| Carrier, O | 3 |
| d'Athis, P | 2 |
| Moran, C | 3 |
| Badoual, J | 3 |
| Olive, G | 3 |
| Wakamatsu, A | 1 |
| Umetsu, M | 1 |
| Motoya, H | 1 |
| Nakao, T | 1 |
| Nadkarni, S | 1 |
| Hay, AW | 1 |
| Faye, S | 1 |
| Congdon, PJ | 1 |
| de Soto, H | 1 |
| Boeckx, R | 1 |
| Krauss, AN | 1 |
| Badonnel, Y | 1 |
| Houdret, N | 1 |
| Broly, F | 1 |
| Roussel, P | 1 |
| Carpentier, C | 1 |
| Zaoui, C | 1 |
| Sacré, L | 1 |
| Vandenplas, Y | 1 |
| Spitzer, AR | 1 |
| Fox, WW | 1 |
| Toubas, PL | 1 |
| Duke, JC | 1 |
| McCaffree, MA | 1 |
| Mattice, CD | 1 |
| Bendell, D | 1 |
| Orr, WC | 1 |
| Davis, JM | 1 |
| Anwar, M | 1 |
| Mondestin, H | 1 |
| Mojica, N | 1 |
| Novo, R | 1 |
| Graff, M | 1 |
| Hiatt, M | 1 |
| Hegyi, T | 1 |
| Reinhardt, D | 1 |
| Kusenbach, G | 1 |
| Le Guennec, JC | 2 |
| Billon, B | 2 |
| Brouard, C | 1 |
| Pajot, N | 1 |
| Walti, H | 1 |
| Spierer, DN | 1 |
| Koyama, EA | 1 |
| Paré, C | 1 |
| Jamain, B | 1 |
| Michon, L | 1 |
| Aubertin, D | 1 |
| Touratier, P | 1 |
| Cormier, JP | 1 |
| Cathely, JP | 1 |
| Moreau, M | 1 |
| Rietveld, HJ | 1 |
| de Wilde, TW | 1 |
Clinical Trials (16)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment With Caffeine of Very Preterm Infant in the Delivery Room: the CAFROOM Feasibility Study[NCT04044976] | 42 participants (Actual) | Interventional | 2019-08-01 | Completed | |||
| Pharmacokinetics (PK) and Safety of Caffeine in Neonates With Hypoxic Ischemic Encephalopathy Receiving Therapeutic Hypothermia[NCT05295784] | Phase 1 | 18 participants (Anticipated) | Interventional | 2024-06-30 | Not yet recruiting | ||
| Efficacy and Safety of Methylxanthines in Very Low Birthweight Infants[NCT00182312] | Phase 3 | 2,000 participants (Anticipated) | Interventional | 1999-10-31 | Completed | ||
| The Effect of Standardizing the Definition and Approach to a Clinically Significant Cardiopulmonary Event in Infants Less Than 30 Weeks on Length of Stay[NCT03414671] | 160 participants (Actual) | Observational | 2018-06-01 | Completed | |||
| Long-Term Effects On Sleep Of Methylxanthine Therapy For Apnea Of Prematurity[NCT01020357] | Phase 3 | 201 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Effect of Early Use of Caffeine Citrate in Preterm Neonates Needing Respiratory Support.[NCT04001712] | Phase 3 | 54 participants (Actual) | Interventional | 2019-04-05 | Completed | ||
| A Randomized, Placebo-controlled Trial of Early Caffeine in Preterm Neonates[NCT03086473] | Phase 4 | 24 participants (Actual) | Interventional | 2017-02-01 | Active, not recruiting | ||
| High Versus Low Dose Caffeine as Respiratory Stimulant in Preterm Infants[NCT04144712] | Phase 1 | 80 participants (Anticipated) | Interventional | 2019-04-01 | Recruiting | ||
| Apneic Oxygenation to Prevent Oxygen Desaturation During Intubation in the NICU[NCT05451953] | 110 participants (Anticipated) | Interventional | 2022-07-21 | Recruiting | |||
| Caffeine Citrate for the Treatment of Apnea Associated With Bronchiolitis in Young Infants: A Randomized, Double Blind, Controlled Trial (RCT)[NCT01435486] | 90 participants (Actual) | Interventional | 2011-11-30 | Completed | |||
| A Prospective, Controlled Trial of Inhalation of Low Concentration of CO2 in Preterm Infants Not Responding to Caffeine for the Treatment of Apnea of Prematurity[NCT01911182] | Phase 2/Phase 3 | 7 participants (Actual) | Interventional | 2011-10-31 | Terminated (stopped due to Low recruitment rate) | ||
| Caffeine for Late Preterm Infants: A Double Blind Randomized Controlled Trial[NCT06026163] | Phase 2/Phase 3 | 134 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| WAVE Trial in Premature Infants With Apnea of Prematurity Using a Simple, Non-invasive Vibratory Device to Study the Effectiveness in Supporting Breathing and General Stability[NCT04528030] | 17 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | |||
| [NCT01066728] | Phase 2/Phase 3 | 87 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia[NCT04447989] | Phase 2 | 120 participants (Anticipated) | Interventional | 2021-05-27 | Recruiting | ||
| Effect of Feedings on Caffeine Pharmacokinetics and Metabolism in Premature Infants[NCT02293824] | 50 participants (Anticipated) | Observational | 2014-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reviews
62 reviews available for caffeine and Apnea
| Article | Year |
|---|---|
Caffeine and bronchopulmonary dysplasia: Clinical benefits and the mechanisms involved.
Topics: Animals; Apnea; Bronchopulmonary Dysplasia; Caffeine; Humans; Infant, Newborn; Infant, Premature; In | 2022 |
Caffeine: Some of the Evidence behind Its Use and Abuse in the Preterm Infant.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa | 2022 |
[Recent research on gene polymorphisms related to caffeine therapy in preterm infants with apnea of prematurity].
Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Infa | 2022 |
Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis.
Topics: Aminophylline; Apnea; Caffeine; Citrates; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases | 2022 |
Caffeine dosing regimens in preterm infants with or at risk for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Child; Humans; Infant; Infant, Extremely Premature; Inf | 2023 |
Effect of prophylactic caffeine in the treatment of apnea in very low birth weight infants: a meta-analysis.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Very Low Birth Weight; Respirat | 2023 |
Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants.
Topics: Aminophylline; Apnea; Birth Weight; Bronchopulmonary Dysplasia; Caffeine; Hearing Loss; Humans; Infa | 2023 |
Doxapram for the prevention and treatment of apnea in preterm infants.
Topics: Aminophylline; Apnea; Caffeine; Doxapram; Humans; Infant, Newborn; Infant, Premature; Lung Diseases | 2023 |
Methylxanthine for the prevention and treatment of apnea in preterm infants.
Topics: Apnea; Caffeine; Cerebral Palsy; Disabled Persons; Humans; Infant; Infant, Newborn; Infant, Prematur | 2023 |
Mechanistic actions of oxygen and methylxanthines on respiratory neural control and for the treatment of neonatal apnea.
Topics: Animals; Apnea; Caffeine; Continuous Positive Airway Pressure; Humans; Infant, Newborn; Infant, Newb | 2020 |
Caffeine Therapy in Preterm Infants: The Dose (and Timing) Make the Medicine.
Topics: Airway Extubation; Apnea; Caffeine; Central Nervous System; Central Nervous System Stimulants; Dose- | 2019 |
Confounding biases in studies on early- versus late-caffeine in preterm infants: a systematic review.
Topics: Apnea; Caffeine; Drug Administration Schedule; Humans; Infant; Infant, Newborn; Infant, Premature; I | 2020 |
Caffeine for the Treatment of Apnea in the Neonatal Intensive Care Unit: A Systematic Overview of Meta-Analyses.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Intensive | 2020 |
Neurodevelopmental outcomes after neonatal caffeine therapy.
Topics: Animals; Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Citrates; D | 2020 |
Caffeine for preterm infants: Fixed standard dose, adjustments for age or high dose?
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Cerebral Hemorrhage; Citrates; Dose-Response Relationsh | 2020 |
National and international guidelines for neonatal caffeine use: Are they evidenced-based?
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Evidence-Based Medicine; Humans; Infan | 2020 |
Caffeine use in the neonatal intensive care unit.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Intensive Care Units, Neonatal | 2017 |
Caffeine controversies.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Drug Administration | 2018 |
High versus standard dose caffeine for apnoea: a systematic review.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Dose-Response Relati | 2018 |
Caffeine: an evidence-based success story in VLBW pharmacotherapy.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Ductus Arteriosus, Patent; Enterocolitis, Necrot | 2018 |
High-versus low-dose caffeine in preterm infants: a systematic review and meta-analysis.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant; Infant Mortality; Infant, Newbor | 2019 |
Efficacy and Safety of Different Maintenance Doses of Caffeine Citrate for Treatment of Apnea in Premature Infants: A Systematic Review and Meta-Analysis.
Topics: Apnea; Caffeine; Citrates; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Prema | 2018 |
Is early caffeine therapy safe and effective for ventilated preterm infants?
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa | 2019 |
Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Drug Monitoring; Humans; Infant, Prema | 2014 |
Caffeine for apnea of prematurity: a neonatal success story.
Topics: Animals; Apnea; Birth Weight; Caffeine; Cost-Benefit Analysis; Drug Costs; Gestational Age; Humans; | 2014 |
An Overview on the Respiratory Stimulant Effects of Caffeine and Progesterone on Response to Hypoxia and Apnea Frequency in Developing Rats.
Topics: Age Factors; Animals; Animals, Newborn; Apnea; Caffeine; Heart Rate; Hypoxia; Progesterone; Rats; Re | 2015 |
Cardiorespiratory events in preterm infants: interventions and consequences.
Topics: Animals; Apnea; Bradycardia; Caffeine; Central Nervous System Stimulants; Continuous Positive Airway | 2016 |
Early Caffeine Use in Very Low Birth Weight Infants and Neonatal Outcomes: A Systematic Review and Meta-Analysis.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Citrates; Enterocolitis, Necrotizing; Humans; Infant; I | 2015 |
The potential of methylxanthine-based therapies in pediatric respiratory tract diseases.
Topics: Adolescent; Apnea; Asthma; Bronchodilator Agents; Caffeine; Child; Child, Preschool; Cough; Humans; | 2016 |
Doxapram Treatment for Apnea of Prematurity: A Systematic Review.
Topics: Apnea; Caffeine; Doxapram; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Premature; Infa | 2017 |
The Role of Caffeine in Noninvasive Respiratory Support.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newb | 2016 |
Caffeine for apnea of prematurity: Effects on the developing brain.
Topics: Animals; Apnea; Brain; Caffeine; Central Nervous System Stimulants; Humans | 2017 |
Nasal CPAP and surfactant for treatment of respiratory distress syndrome and prevention of bronchopulmonary dysplasia.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Citrates; Combined M | 2009 |
[Apnea of prematurity: what's new?].
Topics: Apnea; Bradycardia; Brain Damage, Chronic; Bronchopulmonary Dysplasia; Caffeine; Central Nervous Sys | 2010 |
Interventions for apnoea of prematurity: a personal view.
Topics: Amino Acids; Apnea; Caffeine; Continuous Positive Airway Pressure; Humans; Infant, Newborn; Infant, | 2010 |
Caffeine versus theophylline for apnea in preterm infants.
Topics: Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; | 2010 |
Question 1 Does caffeine treatment for apnoea of prematurity improve neurodevelopmental outcome in later life?
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Cognition Disorders; Developmental Disabilities; | 2010 |
Caffeine impact on neonatal morbidities.
Topics: Animals; Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premat | 2010 |
Apnea of prematurity: pathogenesis and management strategies.
Topics: Apnea; Arrhythmias, Cardiac; Brain Stem; Caffeine; Central Nervous System Stimulants; Continuous Pos | 2011 |
Methylxanthine treatment for apnoea in preterm infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa | 2010 |
Prophylactic methylxanthine for prevention of apnoea in preterm infants.
Topics: Apnea; Bradycardia; Caffeine; Central Nervous System Stimulants; Humans; Hypoxia; Infant, Newborn; I | 2010 |
Caffeine citrate: when and for how long. A literature review.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Humans; Infant, Newborn; Infant, Prema | 2012 |
Treatment of apnea of prematurity.
Topics: Aminophylline; Apnea; Caffeine; Clinical Trials as Topic; Doxapram; Humans; Infant, Newborn; Infant, | 2003 |
Methylxanthines for the treatment of apnea associated with bronchiolitis and anesthesia.
Topics: Anesthesia, General; Apnea; Bronchiolitis; Caffeine; Clinical Trials as Topic; Humans; Infant; Infan | 2004 |
Evidence behind the WHO guidelines: hospital care for children: is caffeine useful in the prevention of apnoea of prematurity?
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Hospitals; Humans; Infant, Newborn; Infant, Prem | 2007 |
Metabolism and pharmacokinetics of theophylline in human neonates, children, and adults.
Topics: Adult; Age Factors; Apnea; Asthma; Biotransformation; Bradycardia; Caffeine; Child; Female; Half-Lif | 1983 |
Pharmacological rationale for the clinical use of caffeine.
Topics: Animals; Apnea; Caffeine; Central Nervous System; Headache; Humans; Hypotension; Obesity; Pain; Phos | 1995 |
Anesthesia and apnea. Perioperative considerations in the former preterm infant.
Topics: Age Factors; Anemia; Anesthesia; Apnea; Bradycardia; Caffeine; Clinical Protocols; Gestational Age; | 1994 |
Pharmacologic management of apnea of prematurity.
Topics: Apnea; Bronchodilator Agents; Caffeine; Drug Monitoring; Humans; Infant, Newborn; Infant, Premature, | 1996 |
Standards of laboratory practice: theophylline and caffeine monitoring. National Academy of Clinical Biochemistry.
Topics: Apnea; Bronchodilator Agents; Caffeine; Drug Monitoring; Humans; Infant, Newborn; Lung Diseases, Obs | 1998 |
Caffeine versus theophylline for apnea in preterm infants.
Topics: Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; | 2000 |
Postoperative caffeine for preventing apnea in preterm infants.
Topics: Anesthesia, General; Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; In | 2000 |
Methylxanthine treatment for apnea in preterm infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa | 2000 |
Current options in the management of apnea of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Doxapram; Humans; Infant, Newborn; Infant, Prema | 2000 |
Caffeine citrate: a review of its use in apnoea of prematurity.
Topics: Apnea; Brain; Caffeine; Central Nervous System Stimulants; Citrates; Drug Combinations; Heart Rate; | 2001 |
Methylxanthine treatment for apnea in preterm infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature; Infa | 2001 |
Prophylactic caffeine to prevent postoperative apnea following general anesthesia in preterm infants.
Topics: Anesthesia, General; Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; In | 2001 |
Apnea in the newborn.
Topics: Aminophylline; Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Humans; In | 2001 |
Theophylline or caffeine: which is best for apnea of prematurity?
Topics: Apnea; Caffeine; Citrates; Drug Combinations; Female; Follow-Up Studies; Humans; Infant, Newborn; In | 2000 |
Methylxanthines in apnea of prematurity.
Topics: Apnea; Caffeine; Hemodynamics; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Respi | 1979 |
Pharmacotherapy of neonatal apnea.
Topics: Apnea; Caffeine; Citrates; Doxapram; Drug Combinations; Humans; Infant, Newborn; Theophylline | 1991 |
Caffeine: a new look at an age-old drug.
Topics: Apnea; Arteriosclerosis; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Neoplasms | 1988 |
Trials
53 trials available for caffeine and Apnea
| Article | Year |
|---|---|
Effect of Prophylactic Caffeine on Noninvasive Respiratory Support in Preterm Neonates Weighing 1250-2000 g: A Randomized Controlled Trial.
Topics: Apnea; Caffeine; Continuous Positive Airway Pressure; Humans; Infant; Infant, Newborn; Infant, Prema | 2022 |
Enteral and Parenteral Treatment with Caffeine for Preterm Infants in the Delivery Room: A Randomised Trial.
Topics: Apnea; Caffeine; Delivery Rooms; Gestational Age; Humans; Infant, Newborn; Infant, Premature | 2023 |
Caffeine citrate maintenance doses effect on extubation and apnea postventilation in preterm infants.
Topics: Airway Extubation; Apnea; Caffeine; Citrates; Continuous Positive Airway Pressure; Double-Blind Meth | 2020 |
[Comparison of the efficacy of domestic and imported caffeine citrate in the treatment of apnea in preterm infants: a prospective randomized double-blind controlled trial].
Topics: Apnea; Caffeine; Citrates; Double-Blind Method; Humans; Infant; Infant, Newborn; Infant, Premature; | 2020 |
Early application of caffeine improves white matter development in very preterm infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Child Development; Diffusion Tensor Imaging; Fem | 2020 |
(Rad 8)Caffeine prophylaxis to improve intermittent hypoxaemia in infants born late preterm: a randomised controlled dosage trial (Latte Dosage Trial).
Topics: Apnea; Caffeine; Female; Humans; Hypoxia; Infant; Infant, Newborn; Infant, Premature; New Zealand; P | 2020 |
Duration of Caffeine for Apnea of Prematurity-A Randomized Controlled Trial.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant; Infant, Newborn; Infant, Prematu | 2021 |
Prophylactic versus therapeutic caffeine for apnea of prematurity: a randomized controlled trial.
Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Ox | 2022 |
A Randomized Controlled Trial Comparing Two Doses of Caffeine for Apnoea in Prematurity.
Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases | 2021 |
Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Child Behavior Disorders; Child De | 2017 |
Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Child Behavior Disorders; Child De | 2017 |
Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Child Behavior Disorders; Child De | 2017 |
Academic Performance, Motor Function, and Behavior 11 Years After Neonatal Caffeine Citrate Therapy for Apnea of Prematurity: An 11-Year Follow-up of the CAP Randomized Clinical Trial.
Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Child Behavior Disorders; Child De | 2017 |
Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity in Preterm (≤34 weeks) Neonates: A Randomized Controlled Trial.
Topics: Aminophylline; Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male | 2017 |
Long-term neurodevelopment outcome of caffeine versus aminophylline therapy for apnea of prematurity.
Topics: Aminophylline; Apnea; Caffeine; Child Development; Cognition Disorders; Developmental Disabilities; | 2017 |
Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Child; Child Development; Double-Blind Method; F | 2018 |
Acute hemodynamic effects of methylxanthine therapy in preterm neonates: Effect of variations in subgroups.
Topics: Aminophylline; Apnea; Caffeine; Dose-Response Relationship, Drug; Echocardiography; Female; Gestatio | 2019 |
Influence of prevention of caffeine citrate on cytokine profile and bronchopulmonary dysplasia in preterm infants with apnea.
Topics: Apnea; Birth Weight; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Citrat | 2020 |
[Clinical effect and safety of different maintenance doses of caffeine citrate in treatment of apnea in very low birth weight preterm infants: a prospective randomized controlled trial].
Topics: Apnea; Caffeine; Child; Citrates; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Very L | 2019 |
The effects of caffeine on heart rate variability in newborns with apnea of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Heart Rate; Humans; Infant, Newborn; Inf | 2014 |
Reduction in developmental coordination disorder with neonatal caffeine therapy.
Topics: Apnea; Caffeine; Child, Preschool; Female; Follow-Up Studies; Humans; Infant; Infant, Newborn; Infan | 2014 |
Long-term effects of caffeine therapy for apnea of prematurity on sleep at school age.
Topics: Actigraphy; Apnea; Caffeine; Central Nervous System Stimulants; Child; Child, Preschool; Double-Blin | 2014 |
High versus low-dose caffeine for apnea of prematurity: a randomized controlled trial.
Topics: Airway Extubation; Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Dose-Response Relat | 2015 |
Apnea of prematurity and caffeine pharmacokinetics: potential impact on hospital discharge.
Topics: Apnea; Caffeine; Drug Monitoring; Female; Gestational Age; Half-Life; Humans; Infant, Newborn; Infan | 2016 |
[Clinical effectiveness of different doses of caffeine for primary apnea in preterm infants].
Topics: Apnea; Birth Weight; Caffeine; Citrates; Female; Gestational Age; Humans; Infant, Newborn; Infant, P | 2016 |
[Effect of caffeine citrate on early pulmonary function in preterm infants with apnea].
Topics: Aminophylline; Apnea; Caffeine; Citrates; Continuous Positive Airway Pressure; Female; Humans; Infan | 2016 |
Caffeine Administration to Prevent Apnea in Very Premature Infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Double-Blind Method; Female; Gestational Age; Hu | 2016 |
Caffeine for the Treatment of Apnea in Bronchiolitis: A Randomized Trial.
Topics: Apnea; Bronchiolitis; Caffeine; Citrates; Double-Blind Method; Female; Humans; Infant; Male | 2016 |
[Effect of early caffeine treatment on the need for respirator therapy in preterm infants with respiratory distress syndrome].
Topics: Apnea; Caffeine; Female; Humans; Infant; Infant, Newborn; Male; Prospective Studies; Respiratory Dis | 2016 |
Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring.
Topics: Apnea; Biological Availability; Caffeine; Central Nervous System Stimulants; Citrates; Dose-Response | 2008 |
Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial.
Topics: Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Drug Therapy, Combination | 2009 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male; Oxygen Inhalati | 2010 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Topics: Apnea; Blindness; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Child Development; Ch | 2012 |
[Pharmacologic study of monohydrated caffeine in the treatment of apnoea of premature infant].
Topics: Administration, Oral; Apnea; Caffeine; Central Nervous System Stimulants; Chromatography, High Press | 2003 |
[Monohydrated caffeine: which dosage is effective in the treatment of apnea of prematurity?].
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Dose-Response Relationship, Drug; Humans; Infant | 2003 |
Olfactory stimulation prevents apnea in premature newborns.
Topics: Apnea; Aromatherapy; Bradycardia; Caffeine; Central Nervous System Stimulants; Combined Modality The | 2005 |
Effects of a divided high loading dose of caffeine on circulatory variables in preterm infants.
Topics: Anterior Cerebral Artery; Apnea; Blood Flow Velocity; Caffeine; Carotid Artery, Internal; Celiac Art | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Caffeine therapy for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Combined Modality Th | 2006 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Long-term effects of caffeine therapy for apnea of prematurity.
Topics: Apnea; Body Size; Caffeine; Central Nervous System Stimulants; Cerebral Palsy; Citrates; Development | 2007 |
Effects of caffeine being studied for treatment of apnea in newborns.
Topics: Apnea; Caffeine; Clinical Trials as Topic; Double-Blind Method; Humans; Infant, Newborn; Infant, New | 1983 |
The efficacy of caffeine in the treatment of recurrent idiopathic apnea in premature infants.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Prospective Studies; Recurren | 1981 |
Cerebral blood flow and left ventricular output in spontaneously breathing, newborn preterm infants treated with caffeine or aminophylline.
Topics: Aminophylline; Analysis of Variance; Apnea; Caffeine; Cerebrovascular Circulation; Humans; Infant, N | 1995 |
Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates.
Topics: Apnea; Bradycardia; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Infant, Prematur | 1995 |
Saliva as a valid alternative to serum in monitoring intravenous caffeine treatment for apnea of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Double-Bli | 1996 |
Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity.
Topics: Apnea; Caffeine; Chromatography, High Pressure Liquid; Female; Gestational Age; Humans; Infant, Newb | 1997 |
Comparison of the effects of theophylline and caffeine on serum erythropoietin concentration in premature infants.
Topics: Anemia; Apnea; Caffeine; Erythropoietin; Humans; Infant, Newborn; Infant, Premature; Infant, Prematu | 1998 |
Low-dose doxapram for treatment of apnoea following early weaning in very low birthweight infants: a randomized, double-blind study.
Topics: Apnea; Blood Pressure; Caffeine; Central Nervous System Stimulants; Double-Blind Method; Doxapram; H | 1998 |
Effect of doxapram on episodes of apnoea, bradycardia and hypoxaemia in preterm infants.
Topics: Apnea; Birth Weight; Bradycardia; Caffeine; Doxapram; Drug Resistance; Gestational Age; Humans; Hypo | 1999 |
Caffeine citrate for the treatment of apnea of prematurity: a double-blind, placebo-controlled study.
Topics: Apnea; Caffeine; Citrates; Double-Blind Method; Drug Combinations; Female; Humans; Infant; Infant, N | 2000 |
Brain hemodynamic changes in preterm infants after maintenance dose caffeine and aminophylline treatment.
Topics: Aminophylline; Apnea; Birth Weight; Blood Flow Velocity; Blood Volume; Caffeine; Central Nervous Sys | 2000 |
Caffeine or theophylline for neonatal apnoea?
Topics: Apnea; Caffeine; Dose-Response Relationship, Drug; Humans; Infant, Newborn; Infant, Premature; Theop | 1992 |
High-dose caffeine suppresses postoperative apnea in former preterm infants.
Topics: Anesthesia, General; Apnea; Bradycardia; Caffeine; Clinical Trials as Topic; Double-Blind Method; He | 1989 |
The effect of caffeine compared with theophylline in the treatment of idiopathic apnea in premature infants.
Topics: Administration, Oral; Apnea; Bradycardia; Caffeine; Clinical Trials as Topic; Double-Blind Method; F | 1989 |
The use of caffeine in the control of post-anesthetic apnea in former premature infants.
Topics: Anesthesia, Inhalation; Apnea; Caffeine; Clinical Trials as Topic; Double-Blind Method; Hernia, Ingu | 1988 |
Theophylline versus caffeine: comparative effects in treatment of idiopathic apnea in the preterm infant.
Topics: Apnea; Caffeine; Double-Blind Method; Heart Rate; Humans; Infant, Newborn; Infant, Premature, Diseas | 1987 |
Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Tachycardia; Theophylline | 1985 |
Other Studies
187 other studies available for caffeine and Apnea
| Article | Year |
|---|---|
Caffeine Duration for Apnea of Prematurity: All Bets Are Off!
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases | 2021 |
Caffeine is a respiratory stimulant without effect on sleep in the short-term in late-preterm infants.
Topics: Apnea; Caffeine; Carbon Dioxide; Central Nervous System Stimulants; Humans; Hypoxia; Infant; Infant, | 2022 |
Caffeine for the Treatment of Central Apnea in Trisomy 18: A Case Study in the Novel Use of Methylxanthines in Palliative Transport.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Infant; Infant, Newborn; Infant, | 2022 |
Caffeine excites medial parabrachial nucleus neurons of mice by blocking adenosine A1 receptor.
Topics: Adenosine; Animals; Apnea; Caffeine; Mice; Neurons; Parabrachial Nucleus; Receptor, Adenosine A1; Re | 2022 |
The Use of Caffeine for Apnoea Associated with Trisomy 13 and Trisomy 18.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Trisomy 13 Syndrome; Trisomy 18 Syndrom | 2021 |
Therapeutic drug monitoring of caffeine and its primary metabolites in plasma using LC-ESI-MS/MS for apnea of prematurity treatment: Evaluation of ultrapure water as a surrogate matrix.
Topics: Animals; Apnea; Caffeine; Drug Monitoring; Humans; Infant, Newborn; Infant, Premature; Rats; Tandem | 2022 |
Effectiveness and safety of early versus late caffeine therapy in managing apnoea of prematurity among preterm infants: a retrospective cohort study.
Topics: Apnea; Caffeine; Cohort Studies; Humans; Infant; Infant, Newborn; Infant, Premature; Retrospective S | 2022 |
Population pharmacokinetic modeling of caffeine in preterm infants with apnea of prematurity: New findings from concomitant erythromycin and AHR genetic polymorphisms.
Topics: Apnea; Caffeine; Erythromycin; Humans; Infant; Infant, Newborn; Infant, Premature; Polymorphism, Gen | 2022 |
The association of salivary caffeine levels with serum concentrations in premature infants with apnea of prematurity.
Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Infa | 2022 |
Evaluation of pharmaceutically compounded oral caffeine on the impact of medication adherence and risk of readmission among preterm neonates: A single-center quasi-experimental study.
Topics: Apnea; Caffeine; Gestational Age; Humans; Infant; Infant, Newborn; Medication Adherence; Patient Rea | 2022 |
It is time for a rethink about caffeine therapy for apnoea of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Newborn, Diseas | 2023 |
Comments on our paper about using caffeine for preterm infants helped to fill knowledge gaps.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Premature | 2023 |
Effects of caffeine on diaphragmatic activity in preterm infants.
Topics: Apnea; Caffeine; Diaphragm; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Premature; Sle | 2023 |
Caffeine for Apnea of Prematurity: Too Much or Too Little of a Good Thing.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newborn; Infant, Newborn, Diseas | 2023 |
Serum caffeine concentrations in preterm infants: a retrospective study.
Topics: Apnea; Caffeine; Gestational Age; Humans; Infant; Infant, Newborn; Infant, Premature; Retrospective | 2023 |
Effects of caffeine therapy for apnea of prematurity on sleep and neurodevelopment of preterm infants at 6 months of corrected age.
Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Premature; Polysomnography; Sleep | 2023 |
Caffeine not associated with irritable behaviour in very low-birth-weight infants.
Topics: Aminophylline; Apnea; Bronchodilator Agents; Caffeine; Central Nervous System Stimulants; Female; Hu | 2019 |
Is earlier better when it comes giving caffeine to preterm infants or are we risking unnecessary treatment and serious harm?
Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases | 2020 |
Wide variation in caffeine discontinuation timing in premature infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Cohort Studies; Combined Modality Ther | 2020 |
Caffeine treatment for bronchiolitis-related apnea in the pediatric intensive care unit.
Topics: Apnea; Bronchiolitis; Caffeine; Case-Control Studies; Central Nervous System Stimulants; Citrates; F | 2020 |
Stopping caffeine in premature neonates: how long does it take for the level of caffeine to fall below the therapeutic range?
Topics: Apnea; Caffeine; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Re | 2022 |
Developmental population pharmacokinetics of caffeine in Chinese premature infants with apnoea of prematurity: A post-marketing study to support paediatric labelling in China.
Topics: Apnea; Caffeine; Child; China; Humans; Infant; Infant, Newborn; Infant, Premature; Marketing | 2021 |
Population pharmacokinetic study of caffeine citrate in Chinese premature infants with apnea.
Topics: Apnea; Asian People; Caffeine; Central Nervous System Stimulants; Citrates; Female; Humans; Infant, | 2020 |
Childhood respiratory outcomes after neonatal caffeine therapy.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Child; Citrates; Duc | 2020 |
When to start and stop caffeine and why respiratory status matters.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Humans; Hypoxia; Infant; Infant, Newbo | 2020 |
Therapy for Apnoea of Prematurity: A Retrospective Study on Effects of Standard Dose and Genetic Variability on Clinical Response to Caffeine Citrate in Chinese Preterm Infants.
Topics: Apnea; Caffeine; China; Citrates; Humans; Infant; Infant, Newborn; Infant, Premature; Reference Stan | 2021 |
Is caffeine available and affordable in low and middle-income countries? A survey in sub-Saharan Africa.
Topics: Africa South of the Sahara; Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Costs and | 2020 |
Pharmacokinetics, pharmacodynamics and metabolism of caffeine in newborns.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Dose-Response Relationship, Drug; Huma | 2020 |
The Pharmacokinetics of Caffeine in Preterm Newborns: No Influence of Doxapram but Important Maturation with Age.
Topics: Apnea; Caffeine; Doxapram; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Di | 2021 |
Are we over-treating hypoxic spells in preterm infants?
Topics: Apnea; Caffeine; Humans; Hypoxia; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Dis | 2021 |
Simultaneous quantitation of serum caffeine and its metabolites by ultra-high-performance liquid chromatography-tandem mass spectrometry for CYP1A2 activity prediction in premature infants.
Topics: Apnea; Caffeine; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1A2; Female; Humans; Infa | 2021 |
Caffeine citrate for apnea of prematurity-One dose does not fit all a prospective study.
Topics: Apnea; Caffeine; Citrates; Humans; Infant; Infant, Newborn; Infant, Premature; Prospective Studies | 2021 |
Neonatal Caffeine Treatment and Respiratory Function at 11 Years in Children under 1,251 g at Birth.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Child; Female; Follow-Up Studies; Humans; Infant, Newbo | 2017 |
Caffeine Citrate Dosing Adjustments to Assure Stable Caffeine Concentrations in Preterm Neonates.
Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Citrates; Dose-Response Relationsh | 2017 |
Pharmacotherapies for apnoea of prematurity: time to pause and consider targeted sex-specific strategies?
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature, Diseases; Male | 2018 |
Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity: Few Concerns.
Topics: Aminophylline; Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2017 |
Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity: Few Concerns: Author's Reply.
Topics: Aminophylline; Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2017 |
[Comparative Study of the Efficacy and Safety of Caffeine and Aminophylline for the Treatment of Apnea in Preterm Infants].
Topics: Administration, Oral; Aminophylline; Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Prema | 2018 |
Effects of caffeine on the preterm brain: An observational study.
Topics: Apnea; Brain; Caffeine; Electroencephalography; Gestational Age; Humans; Infant, Newborn; Infant, Pr | 2018 |
Caffeine therapy for apnoea of prematurity: Wake up to the fact that sex matters.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Retrospective Studies; Sex Ch | 2018 |
Caffeine and supplemental oxygen effectively suppress periodic breathing with only minor effects during long episodes of apnoea in preterm infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Infant, Newborn; Infant, Prematu | 2019 |
The effect of caffeine loading on cerebral autoregulation in preterm infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Cerebrovascular Circulation; Cohort Studies; Fem | 2019 |
Caffeine use in preterm infants: from magic to uncertainty.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Pre | 2018 |
High versus low dose caffeine in preterm infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant; Infant, Newborn; Infant, Prematu | 2019 |
A pilot study of limb stimulation for the treatment of neonatal apnea.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Foot; Hand; Humans; Infant, Newborn; Inf | 2018 |
[Clinical effect of early or late administration of caffeine citrate in prevention and treatment of apnea in very low birth weight infants].
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Child; Citrates; Humans; Infant; Infant, Very Low Birth | 2018 |
High versus low dose caffeine in preterm infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Humans; Infant; Infant, Newborn; Infant, Prematu | 2019 |
Self-reported Quality of Life at Middle School Age in Survivors of Very Preterm Birth: Results From the Caffeine for Apnea of Prematurity Trial.
Topics: Apnea; Caffeine; Case-Control Studies; Central Nervous System Stimulants; Child; Female; Follow-Up S | 2019 |
Dosing and Safety of Off-label Use of Caffeine Citrate in Premature Infants.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Cerebral Hemorrhage; Citrates; Ductus Arteriosus, Paten | 2019 |
The use of caffeine for the treatment of apnea of prematurity and bradycardia in a holoprosencephalic child with cleft lip and palate.
Topics: Apnea; Bradycardia; Caffeine; Central Nervous System Stimulants; Citrates; Cleft Lip; Cleft Palate; | 2013 |
Methylxanthine use for apnea of prematurity among an international cohort of neonatologists.
Topics: Apnea; Australia; Caffeine; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice; | 2013 |
Safety profile comparison between extemporaneous and a licensed preparation of caffeine citrate in preterm infants with apnea of prematurity.
Topics: Apnea; Caffeine; Chemistry, Pharmaceutical; Citrates; Drug-Related Side Effects and Adverse Reaction | 2014 |
Effects of caffeine treatment for apnea of prematurity on cortical speech-sound differentiation in preterm infants.
Topics: Acoustic Stimulation; Analysis of Variance; Apnea; Brain Mapping; Caffeine; Central Nervous System S | 2015 |
Standardizing documentation and the clinical approach to apnea of prematurity reduces length of stay, improves staff satisfaction, and decreases hospital cost.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Documentation; Gestational Age; Hospital Costs; | 2014 |
Current management of apnea in premature infants: is caffeine the magic bullet?
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Respiration, Artificial; Respiratory Sy | 2014 |
Former preterm infants, caffeine was good for you, but now beware of snoring!
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Infant, Premature, Diseases; Mal | 2014 |
Effect of caffeine on preterm infants' cerebral cortical activity: an observational study.
Topics: Apnea; Blood Pressure; Caffeine; Cerebral Cortex; Electroencephalography; Female; Gestational Age; H | 2015 |
Association of early caffeine administration and neonatal outcomes in very preterm neonates.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Canada; Ductus Arteriosus, Patent; Gestational Age; Hum | 2015 |
Association of early caffeine administration and neonatal outcomes in very preterm neonates.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Canada; Ductus Arteriosus, Patent; Gestational Age; Hum | 2015 |
Association of early caffeine administration and neonatal outcomes in very preterm neonates.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Canada; Ductus Arteriosus, Patent; Gestational Age; Hum | 2015 |
Association of early caffeine administration and neonatal outcomes in very preterm neonates.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Canada; Ductus Arteriosus, Patent; Gestational Age; Hum | 2015 |
[Comparison of caffeine citrate and aminophylline for treating primary apnea in premature infants].
Topics: Aminophylline; Apnea; Caffeine; Citrates; Female; Humans; Infant, Newborn; Infant, Premature; Male; | 2014 |
Neonatal caffeine therapy and sleep: important findings to guide new approaches and reduce concerns.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Infant, Premature, Diseases; Mal | 2014 |
Reply: neonatal caffeine therapy and sleep: important findings to guide new approaches and reduce concerns.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Infant, Premature, Diseases; Mal | 2014 |
Very long apnea events in preterm infants.
Topics: Apnea; Bradycardia; Caffeine; Continuous Positive Airway Pressure; Female; Heart Rate; Humans; Infan | 2015 |
Ampakines enhance weak endogenous respiratory drive and alleviate apnea in perinatal rats.
Topics: Analgesics, Opioid; Animals; Animals, Newborn; Apnea; Brain Stem; Caffeine; Disease Models, Animal; | 2015 |
Caffeine in a term neonate with apnea.
Topics: Apnea; Caffeine; Continuous Positive Airway Pressure; Humans; Infant, Newborn; Male; Ventilator Wean | 2015 |
The effect of caffeine citrate on neural breathing pattern in preterm infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Female; Humans; Infant, Newborn; Infan | 2015 |
The Real-World Routine Use of Caffeine Citrate in Preterm Infants: A European Postauthorization Safety Study.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Citrates; Europe; Female; Humans; Infant, Newborn; Infa | 2016 |
Neonatal intensive care unit discharge of infants with cardiorespiratory events: Tri-country comparison of academic centers.
Topics: Academic Medical Centers; Apnea; Caffeine; Canada; Central Nervous System Stimulants; Clinical Decis | 2015 |
Clinical associations of immature breathing in preterm infants: part 1-central apnea.
Topics: Algorithms; Apnea; Caffeine; Cohort Studies; Electrocardiography; Enterocolitis, Necrotizing; Female | 2016 |
Mechanisms of modulation of cytokine release by human cord blood monocytes exposed to high concentrations of caffeine.
Topics: Apgar Score; Apnea; Caffeine; Central Nervous System Stimulants; Comorbidity; Cyclic AMP; Cytokines; | 2016 |
Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates.
Topics: Apnea; Caffeine; Citrates; Drug Monitoring; Female; Heart Rate; Humans; Infant, Newborn; Infant, Pre | 2016 |
DBS-LC-MS/MS assay for caffeine: validation and neonatal application.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Chromatography, Liquid; Dried Blood Spot Testing | 2016 |
[Current research status of drug therapy for apnea of prematurity].
Topics: Aminophylline; Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Disea | 2016 |
Clinically significant cardiopulmonary events and the effect of definition standardization on apnea of prematurity management.
Topics: Apnea; Birth Weight; Caffeine; Disease Management; Female; Gestational Age; Humans; Infant; Infant, | 2017 |
Caffeine for apnea in bronchiolitis.
Topics: Apnea; Bronchiolitis; Caffeine; Humans; Infant, Premature; Infant, Premature, Diseases | 2017 |
Use of caffeine for preterm infants in Australia and New Zealand: A survey.
Topics: Airway Extubation; Apnea; Caffeine; Health Care Surveys; Humans; Infant, Newborn; New Zealand; Pract | 2016 |
Economics of Home Monitoring for Apnea in Late Preterm Infants.
Topics: Ambulatory Care; Apnea; Bradycardia; Caffeine; Central Nervous System Stimulants; Cost Savings; Gest | 2017 |
Atrial arrhythmia after newborn eye exam, to caffeine or not to caffeine?
Topics: Apnea; Atrial Premature Complexes; Bradycardia; Caffeine; Central Nervous System Stimulants; Cyclope | 2016 |
A low cost, simplified, and scaleable pneumotachograph and face mask for neonatal mouse respiratory measurements.
Topics: Animals; Animals, Newborn; Apnea; Caffeine; Central Nervous System Stimulants; Equipment Design; Fem | 2017 |
Respiratory responses to progesterone and allopregnanolone following chronic caffeine treatment in newborn female rats.
Topics: Analysis of Variance; Anesthetics; Animals; Animals, Newborn; Apnea; Caffeine; Carbon Dioxide; Centr | 2017 |
Enhancement of the breathing frequency response to hypoxia by neonatal caffeine treatment in adult male rats: the role of testosterone.
Topics: Age Factors; Animals; Animals, Newborn; Apnea; Caffeine; Central Nervous System Stimulants; Hypoxia; | 2009 |
Acute hemodynamic effects of caffeine administration in premature infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Hemodynamics; Humans; Infant, Newborn; | 2009 |
Caffeine reduces apnea frequency and enhances ventilatory long-term facilitation in rat pups raised in chronic intermittent hypoxia.
Topics: Animals; Animals, Newborn; Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Hypox | 2010 |
Orphan drugs. Viridian Pharma replies.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Drug Costs; Humans; Infant, Newborn; Orphan Drug | 2010 |
Economic evaluation of caffeine for apnea of prematurity.
Topics: Apnea; Caffeine; Cost-Benefit Analysis; Female; Humans; Infant, Newborn; Infant, Premature, Diseases | 2011 |
Archimedes: Does caffeine treatment for apnoea of prematurity improve neurodevelopmental outcome in later life?
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Developmental Disabilities; Humans; Infant, Newb | 2011 |
Alteration of carotid body chemoreflexes after neonatal intermittent hypoxia and caffeine treatment in rat pups.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Apnea; Body Temperature; Body Weight; | 2011 |
What are the main research findings during the last 5 years that have changed my approach to clinical practice?
Topics: Apnea; Caffeine; Humans; Hypothermia, Induced; Hypoxia-Ischemia, Brain; Infant, Extremely Premature; | 2013 |
Neuroprotection for premature infants?: another perspective on caffeine.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Cognition Disorders; Female; Humans; Infant, Pre | 2012 |
Caffeine therapy in neonatal intensive care.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Child Development; Child, Preschool; Humans; Inf | 2012 |
Caffeine as treatment for bronchiolitis-related apnoea.
Topics: Apnea; Bronchiolitis; Caffeine; Female; Humans; Infant, Newborn; Infant, Premature; Infant, Prematur | 2012 |
Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants.
Topics: Apnea; Birth Weight; Caffeine; Central Nervous System Agents; Dried Blood Spot Testing; Female; Gest | 2013 |
Effects of caffeine and/or nasal CPAP treatment on laryngeal chemoreflexes in preterm lambs.
Topics: Animals; Animals, Newborn; Apnea; Arterial Pressure; Bradycardia; Caffeine; Continuous Positive Airw | 2013 |
Influence of age, body temperature, GABAA receptor inhibition and caffeine on the Hering-Breuer inflation reflex in unanesthetized rat pups.
Topics: Aging; Animals; Animals, Newborn; Apnea; Body Temperature; Caffeine; Central Nervous System Stimulan | 2013 |
[IS SUBARACHNOID ADMINISTRATION OF CAFFEINE IN APNEA DURING HIGH SPINAL ANESTHESIA?].
Topics: Anesthesia; Anesthesia, Spinal; Anesthesiology; Apnea; Caffeine; Humans | 1963 |
[PRINCIPAL HAZARDS OF SPINAL ANESTHESIA AND METHODS FOR THEIR ELIMINATION].
Topics: Adjuvants, Anesthesia; Anesthesia; Anesthesia, Spinal; Anesthesiology; Apnea; Blood Pressure; Blood | 1963 |
Apnoeas in bronchiolitis: is there a role for caffeine?
Topics: Apnea; Bronchiolitis; Caffeine; Central Nervous System Stimulants; Humans; Infant | 2005 |
Long-term consequences of neonatal caffeine on ventilation, occurrence of apneas, and hypercapnic chemoreflex in male and female rats.
Topics: Animals; Animals, Newborn; Apnea; Caffeine; Central Nervous System Stimulants; Female; Humans; Hyper | 2006 |
Caffeine for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Humans; Infant, Newb | 2006 |
Correlation between plasma and urinary caffeine levels in preterm infants.
Topics: Apnea; Caffeine; Female; Gestational Age; Humans; Infant, Newborn; Infant, Premature; Male | 2006 |
[Caffeine citrate utilization for treatment of apnea in French neonatal units].
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Citrates; Dose-Response Relationship, Drug; Drug | 2006 |
[Apnea of prematurity: risk factors and ambulatory treatment with caffeine citrate].
Topics: Ambulatory Care; Apnea; Birth Weight; Caffeine; Central Nervous System Stimulants; Citrates; Continu | 2006 |
Caffeine for apnea of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Diuresis; Growth; Humans; Infant, Low Birth Weig | 2006 |
Caffeine for apnea of prematurity.
Topics: Apnea; Bronchopulmonary Dysplasia; Caffeine; Central Nervous System Stimulants; Ductus Arteriosus, P | 2006 |
Serum caffeine concentrations in preterm neonates.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Cross-Sectional Studies; Female; Gestational Age | 2007 |
Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise?
Topics: Apnea; Caffeine; Citrates; Drug Monitoring; Humans; Infant, Newborn; Infant, Premature | 2007 |
On the caffeination of prematurity.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Developmental Disabilities; Humans; Infant, Newb | 2007 |
Use of caffeine in neonates.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Newborn, Diseases | 1984 |
Ontogeny of human caffeine and theophylline metabolism.
Topics: Adult; Aged; Apnea; Caffeine; Child; Child, Preschool; Half-Life; Humans; Infant; Infant, Newborn; I | 1984 |
Maternal coffee drinking and unusually high concentrations of caffeine in the newborn.
Topics: Apnea; Caffeine; Coffee; Female; Half-Life; Humans; Infant, Newborn; Male; Maternal-Fetal Exchange; | 1984 |
Effect of caffeine on control of breathing in infantile apnea.
Topics: Apnea; Caffeine; Dose-Response Relationship, Drug; Humans; Infant, Newborn; Maximal Voluntary Ventil | 1983 |
T4 levels in methylxanthine-treated premature newborns.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Retrospective Studies; Theoph | 1983 |
Interaction of caffeine and continuous distending airway pressure in neonatal apnea.
Topics: Apnea; Caffeine; Combined Modality Therapy; Humans; Infant, Newborn; Infant, Premature, Diseases; Lu | 1983 |
Effects of caffeine in the treatment of apnea.
Topics: Animals; Apnea; Caffeine; Cerebrovascular Circulation; Coronary Circulation; Humans; Infant, Newborn | 1984 |
The metabolic effects of caffeine in the newborn infant.
Topics: Apnea; Blood Glucose; Caffeine; Catecholamines; Electrolytes; Heart Rate; Homeostasis; Humans; Infan | 1981 |
Plasma theophylline and caffeine and plasma clearance of theophylline during theophylline treatment in the first year of life.
Topics: Apnea; Caffeine; Gestational Age; Humans; Infant, Newborn; Infant, Premature, Diseases; Theophylline | 1983 |
Plasma xanthine levels in premature infants treated for apnoea with theophylline.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Theophylline; Xanth | 1983 |
Apnea associated with theophylline withdrawal in a term neonate.
Topics: Apnea; Caffeine; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Maternal-Fetal Exchange | 1982 |
Pharmacokinetic aspects of caffeine in premature infants with apnoea.
Topics: Apnea; Caffeine; Female; Half-Life; Humans; Infant; Infant, Newborn; Infant, Premature, Diseases; Ki | 1982 |
Cross validation of serum to saliva relationships of caffeine, theophylline and total methylxanthines in neonates.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Saliva; Theophylline; Xanthin | 1982 |
[Use of caffeine in the treatment of apnea in premature infants].
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Theophylline; Time | 1982 |
Effect of serum caffeine level on pneumocardiogram of premature infants treated for apnea with theophylline.
Topics: Apnea; Caffeine; Electrocardiography; False Negative Reactions; Humans; Infant, Newborn; Infant, New | 1982 |
Caffeine and theophylline: serum/CSF correlation in premature infants.
Topics: Apnea; Blood-Brain Barrier; Caffeine; Chromatography, Liquid; Humans; Infant, Newborn; Infant, Prema | 1980 |
Pharmacologic considerations in the therapy of neonatal apnea.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Newborn, Diseases; Monitoring, Physiologic; Theoph | 1981 |
Relationship of dose and plasma concentrations of caffeine and ventilation in neonatal apnea.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Kinetics; Re | 1981 |
Methylxanthines in serum, saliva, and spinal fluid of premature infants.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Newborn, Diseases; Infant, Premature; Kinetics; Sa | 1981 |
Adverse effects of caffeine and theophylline in the newborn infant.
Topics: Apnea; Asphyxia Neonatorum; Caffeine; Cardiovascular System; Central Nervous System; Digestive Syste | 1981 |
[Pharmacokinetics of theophylline and caffeine in premature infants with apnea (author's transl)].
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Protein Binding; Th | 1981 |
Use of salivary concentrations in the prediction of serum caffeine and theophylline concentrations in premature infants.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Regression Analysis; Saliva; | 1980 |
Simultaneous determination of theophylline and caffeine after extractive alkylation in small volumes of plasma by gas chromatography--mass spectrometry.
Topics: Alkylation; Apnea; Caffeine; Gas Chromatography-Mass Spectrometry; Humans; Infant, Newborn; Infant, | 1980 |
Plasma beta-endorphin concentration and xanthine treatment in apnea of prematurity.
Topics: Apnea; beta-Endorphin; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Xanthine; Xan | 1993 |
Individualizing aminophylline doses in premature infants using bioelectrical impedance: a non-invasive approach.
Topics: Aminophylline; Apnea; Caffeine; Electric Impedance; Female; Humans; Infant, Newborn; Infant, Prematu | 1993 |
Aminophylline versus caffeine citrate...
Topics: Aminophylline; Apnea; Bradycardia; Caffeine; Cardiotonic Agents; Citrates; Clinical Trials as Topic; | 1995 |
Apnea following spinal anaesthesia in two former pre-term infants.
Topics: Age Factors; Anesthesia, Spinal; Anesthetics, Local; Apnea; Benzoates; Bradycardia; Caffeine; Centra | 1998 |
The effect of theophylline on apnoea and hypoxaemic episodes in the premature neonate during the 1st 3 days after birth.
Topics: Apnea; Blood Pressure; Bradycardia; Bronchodilator Agents; Caffeine; Female; Gestational Age; Humans | 1998 |
Caffeine overdose in a premature infant: clinical course and pharmacokinetics.
Topics: Age Factors; Apnea; Caffeine; Central Nervous System Stimulants; Drug Overdose; Female; Humans; Infa | 1999 |
Caffeine in the treatment of apnea associated with respiratory syncytial virus infection in neonates and infants.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Critical Care; Data Interpretation, Statistical; | 2000 |
Prediction of postdischarge complications by predischarge event recordings in infants with apnea of prematurity.
Topics: Apnea; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Infant, Premature; Infant, Pr | 2000 |
Pharmacokinetics of theophylline and caffeine after intravenous administration of aminophylline to premature neonates in Korea.
Topics: Aminophylline; Apnea; Caffeine; Chromatography, High Pressure Liquid; Female; Half-Life; Humans; Inf | 1999 |
Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea.
Topics: Apnea; Body Weight; Caffeine; Energy Metabolism; Humans; Infant, Newborn; Infant, Premature, Disease | 2001 |
Postoperative recovery after inguinal herniotomy in ex-premature infants and the use of caffeine.
Topics: Apnea; Caffeine; Central Nervous System Stimulants; Hernia, Inguinal; Humans; Infant; Infant, Newbor | 2002 |
Caffeine in apnoeic Asian neonates: a sparse data analysis.
Topics: Apnea; Asia; Body Weight; Caffeine; Central Nervous System Stimulants; Chromatography, High Pressure | 2002 |
Efficacy of caffeine in treatment of apnea in the low-birth-weight infant.
Topics: Apnea; Caffeine; Carbon Dioxide; Drug Evaluation; Humans; Hydrogen-Ion Concentration; Infant, Low Bi | 1977 |
Biotransformation of theophylline to caffeine in premature newborn.
Topics: Administration, Oral; Apnea; Biotransformation; Caffeine; Humans; Infant, Newborn; Infant, Premature | 1978 |
Methylation of theophylline to caffeine in premature infants.
Topics: Apnea; Biotransformation; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Methylatio | 1979 |
Sequelae of caffeine treatment in preterm infants with apnea.
Topics: Apnea; Caffeine; Child Development; Female; Follow-Up Studies; Humans; Infant, Low Birth Weight; Inf | 1979 |
Pharmacokinetic profile of caffeine in the premature newborn infant with apnea.
Topics: Administration, Oral; Apnea; Caffeine; Half-Life; Humans; Infant, Newborn; Infant, Premature, Diseas | 1979 |
Plasma xanthine levels in low birthweight infants treated or not treated with theophylline.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Metabolic Clearance Rate; Mil | 1979 |
Interconversion of theophylline and caffeine in newborn infants.
Topics: Age Factors; Apnea; Biotransformation; Caffeine; Humans; Infant, Newborn; Infant, Premature, Disease | 1979 |
Metabolism of theophylline to caffeine in premature newborn infants.
Topics: Adult; Apnea; Biotransformation; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; The | 1979 |
Caffeine, a metabolite of theophylline during the treatment of apnea in the premature infant.
Topics: Apnea; Caffeine; Half-Life; Humans; Infant, Newborn; Infant, Premature, Diseases; Kinetics; Theophyl | 1979 |
Relationship of plasma and CSF concentrations of caffeine in neonates with apnea.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases | 1979 |
Metabolism of theophylline to caffeine in human fetal liver.
Topics: Apnea; Biotransformation; Caffeine; Cells, Cultured; Gestational Age; Humans; Infant, Newborn; Liver | 1979 |
Apneic spells and transcutaneous PO2: treatment with caffeine, 19-year follow-up.
Topics: Apnea; Blood Gas Analysis; Blood Pressure; Caffeine; Diagnosis, Differential; Follow-Up Studies; Hea | 1979 |
Micro-method for the determination of caffeine and theophylline allowing direct application of biological fluids to thin-layer chromatography plates.
Topics: Apnea; Caffeine; Child; Child, Preschool; Chromatography, Thin Layer; Female; Humans; Infant; Infant | 1978 |
The xanthine treatment of apnea of prematurity.
Topics: Aminophylline; Apnea; Bradycardia; Caffeine; Humans; Hypoxia; Infant, Newborn; Infant, Premature, Di | 1975 |
[Effects of coffee on the respiratory system].
Topics: Adult; Apnea; Bronchial Neoplasms; Caffeine; Coffee; Female; Humans; Infant, Newborn; Infant, Newbor | 1992 |
Effectiveness and side effects of two different doses of caffeine in preventing apnea in premature infants.
Topics: Apnea; Blood Gas Monitoring, Transcutaneous; Blood Pressure; Caffeine; Humans; Infant, Newborn; Infa | 1992 |
Severe caffeine intoxication in a preterm neonate.
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Male | 1992 |
Percutaneous caffeine application in the treatment of neonatal apnoea.
Topics: Administration, Cutaneous; Apnea; Caffeine; Chromatography, High Pressure Liquid; Citrates; Drug Com | 1991 |
[Importance of monitoring theophylline and caffeine plasma levels in the management of neonatal apnea].
Topics: Apnea; Asphyxia Neonatorum; Caffeine; Humans; Infant, Newborn; Monitoring, Physiologic; Theophylline | 1991 |
[Caffeine in the treatment of apnea in premature infants].
Topics: Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases | 1990 |
[Efficacy of percutaneous caffeine in the treatment of apnea in the premature infant].
Topics: Administration, Cutaneous; Apnea; Caffeine; Humans; Infant, Newborn; Infant, Premature, Diseases; Ma | 1990 |
Cardiovascular effects of caffeine therapy in preterm infants.
Topics: Apnea; Blood Pressure; Caffeine; Cardiac Output; Heart; Heart Rate; Humans; Infant, Newborn; Infant, | 1990 |
Does caffeine affect cerebral blood flow in the preterm infant?
Topics: Apnea; Blood Gas Monitoring, Transcutaneous; Caffeine; Cerebrovascular Circulation; Humans; Infant; | 1989 |
Caffeine citrate in the NICU.
Topics: Apnea; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Infant, Premature, Diseases; | 1989 |
Caffeine citrate. Pointers in practical pharmacology.
Topics: Apnea; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Infant, Premature, Diseases | 1989 |
Transplacentally acquired caffeine and the occurrence of apnea, bradycardia, and periodic breathing in preterm infants: preliminary communication.
Topics: Apnea; Bradycardia; Caffeine; Cheyne-Stokes Respiration; Chromatography, High Pressure Liquid; Femal | 1989 |
Low-dose doxapram for apnoea of prematurity.
Topics: Apnea; Caffeine; Doxapram; Drug Therapy, Combination; Humans; Infant, Newborn; Infant, Premature, Di | 1986 |
Oral versus intramuscular loading of caffeine in idiopathic apnoea of prematurity.
Topics: Administration, Oral; Apnea; Blood Glucose; Caffeine; Humans; Infant, Newborn; Infant, Premature, Di | 1988 |
Maturation of caffeine N-demethylation in infancy: a study using the 13CO2 breath test.
Topics: Apnea; Breath Tests; Caffeine; Carbon Dioxide; Chromatography, High Pressure Liquid; Gestational Age | 1988 |
Change of plasma half-life of caffeine during caffeine therapy for apnea in premature infants.
Topics: Apnea; Caffeine; Half-Life; Humans; Infant, Newborn; Infant, Premature | 1987 |
Developmental changes of caffeine elimination in infancy.
Topics: Aging; Apnea; Caffeine; Drug Administration Schedule; Gestational Age; Half-Life; Humans; Infant; In | 1988 |
The relationship between theophylline, caffeine and heart rate in neonates.
Topics: Aminophylline; Apnea; Caffeine; Heart Rate; Humans; Infant, Newborn; Infant, Premature; Theophylline | 1988 |
Maturation of caffeine metabolic pathways in infancy.
Topics: Acetylation; Administration, Oral; Adult; Age Factors; Apnea; Caffeine; Chromatography, High Pressur | 1988 |
Apnea in infancy: pathophysiology, diagnosis, and treatment.
Topics: Aminophylline; Apnea; Caffeine; Chemoreceptor Cells; Home Nursing; Humans; Infant; Infant, Newborn; | 1986 |
Simultaneous administration of caffeine and phenobarbitone in infants with apnea.
Topics: Apnea; Caffeine; Drug Therapy, Combination; Half-Life; Humans; Infant; Infant, Newborn; Infant, Prem | 1987 |
[Xanthines in apnea of premature infants. Influence on gastroesophageal reflux].
Topics: Apnea; Caffeine; Gastroesophageal Reflux; Humans; Infant, Newborn; Infant, Premature, Diseases; Xant | 1987 |
Infant apnea.
Topics: Airway Obstruction; Apnea; Bradycardia; Caffeine; Cardiography, Impedance; Home Nursing; Humans; Inf | 1986 |
Effects of maternal smoking and caffeine habits on infantile apnea: a retrospective study.
Topics: Apnea; Birth Weight; Caffeine; Female; Humans; Infant, Newborn; Maternal Age; Pregnancy; Prenatal Ex | 1986 |
Apnoea and seizures.
Topics: Apnea; Caffeine; Electroencephalography; Female; Humans; Infant; Male; Seizures | 1986 |
Effect of caffeine on pneumogram and apnoea of infancy.
Topics: Apnea; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Infant, Premature, Diseases; | 1986 |
[Peculiarities of drug therapy in childhood].
Topics: Apnea; Biological Availability; Biotransformation; Caffeine; Child; Child, Preschool; Dexamethasone; | 1986 |
Delay in caffeine elimination in breast-fed infants.
Topics: Apnea; Biological Availability; Bottle Feeding; Breast Feeding; Caffeine; Fatty Acids, Nonesterified | 1987 |
Caffeine citrate: an alternative to theophylline for apnea in prematurity.
Topics: Apnea; Caffeine; Citrates; Drug Combinations; Humans; Infant, Newborn; Theophylline | 1985 |
Maturational changes of caffeine concentrations and disposition in infancy during maintenance therapy for apnea of prematurity: influence of gestational age, hepatic disease, and breast-feeding.
Topics: Aging; Apnea; Breast Feeding; Caffeine; Cholestasis; Citrates; Drug Combinations; Gestational Age; H | 1985 |
[Resuscitation of the newborn].
Topics: Acidosis, Respiratory; Apnea; Bicarbonates; Caffeine; Catheterization; Cyanosis; Equipment and Suppl | 1969 |
[Apnea periods in the premature infant].
Topics: Apnea; Caffeine; Heart Rate; Humans; Infant, Newborn; Infant, Premature, Diseases; Monitoring, Physi | 1974 |